Stockwinners Market Radar for June 02, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EDT Alarm.com CEO sells 40.3K shares of common stock - In a regulatory filing, Alarm.com disclosed that its CEO Stephen Trundle sold 40.3K shares of common stock on May 28th in a total transaction size of $3.30M, reducing his stake by about 2%.

19:47 EDT Incoming Skillsoft CEO to discuss merger with Churchill Capital Corp II - Churchill Capital Corp II announced Jeff Tarr, incoming CEO of Skillsoft and Larry Illg, CEO of EdTech for Prosus will participate in a fireside chat webinar to discuss the pending merger of Skillsoft, Global Knowledge Training LLC and Churchill II.

19:14 EDT Volaris reports May passenger traffic up 12% from pre-pandemic levels - Volaris reports its May 2021 preliminary traffic results. In May 2021, demand in the domestic Mexican and international markets for Volaris increased 16.3% and 19.3%, compared to May 2019, respectively. The company capitalized on opportunities to add capacity, both domestically and internationally, while maintaining a high load factor. In May 2021, Volaris transported 2.2M passengers, 12% higher than the pre-pandemic levels.

18:31 EDT BigCommerce CEO sells 31.9K shares of common stock - In a regulatory filing, BigCommerce disclosed that its CEO Brent Bellm sold 31.9K shares of common stock on May 28th in a total transaction size of $1.77M, reducing his stake by about 1%.

18:10 EDT RealReal jumps about 4.5% to $18.90 after disclosing QTD GMV data

17:43 EDT First Savings Financial Group increases dividend 100% to 36c per share - First Savings Financial Group declared a quarterly cash dividend of 36c per common share, a 100% increase from the prior quarter's amount. The dividend will be paid on or about June 30 to stockholders of record as of the close of business on June 16.

17:42 EDT Twitter debuts Birdwatch fact checking in tweets - Twitter said earlier, in a tweet thread on Twitter: "Hey there! Exciting news Party popper. Now, when you're browsing Twitter on Android, iOS, or https://Twitter.com, you may see Tweets with Birdwatch notes. Notes will appear in a card on the Tweet. Right now, this feature is only visible to pilot participants.Why show notes on Tweets? Birdwatch wants to help people stay informed by adding helpful context to Tweets. This feature will allow those who are currently participating in Birdwatch to more easily identify and rate the most helpful notes.So, how does it work?! If a Tweet has a Birdwatch note that is "Currently rated helpful" then you'll see that note right there on the Tweet, and you can rate it to help elevate the most helpful notes....Finally, if all notes on a Tweet are "Currently not rated helpful," there won't be a card on the Tweet. You'll still be able to get to Birdwatch notes on that Tweet by clicking on the Birdwatch icon in the Tweet details page." Reference Link

17:26 EDT Shoe Carnival CEO sells 40K shares of common stock - In a regulatory filing, Shoe Carnival disclosed that its CEO Clifton Sifford sold 40K shares of common stock on May 27th in a total transaction size of $2.8M, reducing his stake by about 22%.

17:14 EDT Ennis acquires assets of AmeriPrint Corporation - Ennis announced its acquisition of the assets and business from AmeriPrint Corporation in Harvard, Illinois. The closing occurred on Monday, May 31. AmeriPrint Corporation is a trade printer specializing in custom-printed documents, barcoding, integrated products, and business forms. Upon closing, AmeriPrint operations will continue to operate as AmeriPrint. All facilities will continue their normal operations in their current location.

17:01 EDT Bombardier confirms deal with U.S. Air Force for up to six more global aircraft - Bombardier confirmed an agreement between its Learjet Inc. subsidiary and the U.S. Air Force in support of the Battlefield Airborne Communications Node program. The Indefinite Delivery Indefinite Quantity contract provides the USAF with flexible ordering and includes an immediate firm order for one Global 6000 aircraft, with as many as five additional Global 6000 aircraft. The contract, which includes engineering and modification work, represents a potential total value of close to $465M. Bombardier has already delivered four Global aircraft to the U.S. Air Force since 2007 for the BACN program, an airborne relay that extends communication ranges, bridges between radio frequencies and "translates" among incompatible communications systems. BACN aircraft are known in the U.S. Air Force as the E-11A. "Bombardier is proud to be chosen once again by the U.S. Air Force to provide our high-performing Global aircraft and our unique expertise in support of the BACN program," said Michel Ouellette, Executive Vice President, Specialized Aircraft, Programs and Engineering, Bombardier. "Our U.S.-based employees are honored to be lending their skills in support of this elite project."

16:55 EDT SEI Investments raises share repurchase program by $250M - The Board of Directors of SEI Investments Company approved an increase in its stock repurchase program by an additional $250M, increasing the available authorization under the program to approximately $316M.

16:37 EDT Accenture names CEO Julie Sweet to additional position of Chair of the Board - The board of directors of Accenture has named CEO Julie Sweet to the additional position of chair of the board, effective September 1. She succeeds David Rowland, who will step down as executive chairman and from the board on that date. Sweet succeeded Rowland as CEO on September 1, when she also joined the Accenture board of directors.

16:32 EDT Valaris announces jackup contract award - Valaris announced that it has been awarded a two-well contract extension with Equinor Energy AS offshore Norway for VALARIS JU-291, a heavy-duty ultra-harsh environment jackup. The extension is for an estimated 120 days in direct continuation of the existing contract and, as a result, the VALARIS JU-291 is now expected to be under contract through February 2022.

16:27 EDT Idexx Laboratories acquires ezyVet - IDEXX Laboratories announced the acquisition of ezyVet, a fast-growing, innovative practice information management system, PIMS. With the acquisition, IDEXX further expands its world-class cloud software offerings that support customers with technology solutions that raise the standard of care for patients, improve practice efficiency, and enable more effective communication with pet owners.

16:21 EDT Churchill Downs suspends trainer Bob Baffert for two years - Churchill Downs announced the suspension of trainer Bob Baffert for two years effective immediately through the conclusion of the 2023 Spring Meet at Churchill Downs Racetrack. The suspension prohibits Baffert, or any trainer directly or indirectly employed by Bob Baffert Racing Stables, from entering horses in races or applying for stall occupancy at all Churchill Downs-owned racetracks. "This decision follows the confirmation by attorneys representing Bob Baffert of the presence of betamethasone, a prohibited race-day substance, in Medina Spirit's bloodstream on the day of the 147th running of the Kentucky Derby in violation of the Commonwealth of Kentucky's equine medication protocols and CDI's terms and conditions for racing," the company said in a statement. Bill Carstanjen, CEO of Churchill Downs Incorporated, added, "Reckless practices and substance violations that jeopardize the safety of our equine and human athletes or compromise the integrity of our sport are not acceptable and as a company we must take measures to demonstrate that they will not be tolerated. Mr. Baffert's record of testing failures threatens public confidence in thoroughbred racing and the reputation of the Kentucky Derby. Given these repeated failures over the last year, including the increasingly extraordinary explanations, we firmly believe that asserting our rights to impose these measures is our duty and responsibility."

16:20 EDT Supernova Partners Acquisition Company III receives NYSE delay notification - Supernova Partners Acquisition Company III received a notice from the NYSE indicating that it is not in compliance with NYSE continued listing requirements under the timely filing criteria as a result of its failure to timely file the Form 10-Q for the fiscal quarter ended March 31. The Notice has no immediate effect on the listing or trading of the company's securities on the NYSE. Given the scope of the process for evaluating the impact of the SEC statement "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies" on the company's financial statements, the company was unable to file the Form 10-Q within the prescribed time period without unreasonable effort or expense. Since receiving the non-compliance notice, the company continues to work with its independent accounting firm in order to file the Form 10-Q as expeditiously as practicable. The company is in compliance with all other NYSE continued listing requirements.

16:18 EDT PVH Corp. says international revenue in Q1 exceeded 2019 pre-pandemic levels - The company statess: "Revenue in the company's international businesses exceeded 2019 pre-pandemic levels. Revenue through digital channels grew approximately 95%, with sales through its directly operated digital commerce businesses up 66% as compared to the prior year period. Digital penetration as a percentage of total revenue was approximately 25%."

16:17 EDT Supernova Partners Acquisition receives NYSE notice of non-compliance - Supernova Partners Acquisition Company announced that, on May 25, it received a notice from the New York Stock Exchange indicating that it was not in compliance with NYSE continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file the Form 10-Q for the fiscal quarter ended March 31. The Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the company's securities on the NYSE.

16:13 EDT Smartsheet jumps over 2% to $61.50 after Q1 results and guidance

16:11 EDT VG Acquisition recommends shareholders vote in favor of 23andMe combination - VG Acquisition's board issued a recommendation that shareholders vote in favor of the company's proposed business combination with 23andMe, a consumer genetics and research company, and the related proposals that will come before VGAC's extraordinary general meeting of shareholders. The Special Meeting is scheduled for June 10 at 10:00 a.m. ET to approve, among other things, the business combination with 23andMe. Shareholders of record as of the close of business on May 5 are entitled to vote on matters that come before the Special Meeting. The company asks that all shareholders vote their shares regardless of how many shares they hold. If the proposals at the Special Meeting are approved, the closing of the business combination is currently expected to occur on June 16. Upon the closing, VGAC will change its name to 23andMe Holding , or "New 23andMe", and New23andMe Class A common stock and New23andMe warrants will be listed on Nasdaq. Trading is expected to begin on Nasdaq on June 17, 2021, under the new ticker symbol "ME" for the New23andMe Class A common stock and "MEUSW" for the New23andMe warrants.

16:09 EDT Dyne Therapeutics announces Chief Scientific Officer transition - Dyne Therapeutics announced that Romesh Subramanian, Ph.D. has chosen to step down as Chief Scientific Officer for personal reasons and will continue to serve as an advisor to Dyne. Concurrently, Oxana Beskrovnaya, Ph.D., who has served as Dyne's senior VP, head of research since January 2020, has been appointed Chief Scientific Officer.

16:06 EDT Adobe names David Wadhwani as EVP, Chief Business Officer of Digital Media - Adobe announced the appointment of David Wadhwani as executive vice president and chief business officer, Digital Media. In this role, Wadhwani will be responsible for the success of Adobe's global Digital Media business across Adobe Creative Cloud and Adobe Document Cloud, including all product marketing, strategic partnerships, customer support and go-to-market across geographies, working closely with the Digital Media Product organizations. He will report directly to Adobe president and CEO Shantanu Narayen. Wadhwani previously served as senior vice president and general manager of Adobe's Digital Media business from 2010 to 2015.

16:05 EDT FireEye board approves share repurchase program of up to $500M - FireEye announced that its Board of Directors has approved a share repurchase program for up to $500M of outstanding FireEye common stock. Repurchases may be made at management's discretion from time to time on the open market, through privately negotiated transactions and through Rule 10b5-1 plans. The repurchase program has no termination date and may be suspended for periods, amended or discontinued at any time. Any shares acquired will be available for general corporate purposes.

16:04 EDT FireEye to sell FireEye Products to Symphony consortium for $1.2B - FireEye announced it has entered into a definitive agreement to sell the FireEye Products business, including the FireEye name, to a consortium led by Symphony Technology Group in an all-cash transaction for $1.2B, before taxes and transaction-related expenses. The transaction is expected to close by the end of the fourth quarter of 2021, subject to customary regulatory approvals and closing conditions, and will separate FireEye's network, email, endpoint, and cloud security products, along with the related security management and orchestration platform, from Mandiant's controls-agnostic software and services, enabling both organizations to accelerate growth investments, pursue new go-to-market pathways, and focus innovation on their respective solutions. The FireEye Products business and Mandiant Solutions will continue to operate as a single entity until the transaction closes, allowing management and STG to develop a successful transition of the FireEye Products business to a standalone entity within the STG portfolio. "We believe this separation will unlock our high-growth Mandiant Solutions business and allow both organizations to better serve customers," said FireEye Chief Executive Officer Kevin Mandia. "After closing, we will be able to concentrate exclusively on scaling our intelligence and frontline expertise through the Mandiant Advantage platform, while the FireEye Products business will be able to prioritize investment on its cloud-first security product portfolio. STG's focus on fueling innovative market leaders in software and cybersecurity makes them an ideal partner for FireEye Products. We look forward to our relationship and collaboration on threat intelligence and expertise."

16:02 EDT NetApp reports Q4 billings up 12% at 1.74B - NetApp public cloud services annualized revenue run rate, or ARR, increased 171% year-over-year to $301 million.

15:53 EDT Apple says Apple Card outage resolved - Apple said in a system status message: "Apple Card - Resolved Outage - Today, 9:17 AM - 3:19 PM - Users may not have been able to manage their Apple Card, make payments, and may not have seen recent transactions." Reference Link

15:00 EDT Xerox acquires Document Systems, terms not disclosed - Xerox has acquired Document Systems, a document solutions provider in Southern California. "We're focused on strengthening our U.S. small and midsize business (SMB) market reach through the combined power of our portfolio of workplace solutions for SMBs and well-established local technology providers," said Joanne Collins Smee, chief commercial, SMB and channels officer at Xerox. "As part of Xerox Business Solutions (XBS), Document Systems' document management expertise will help us elevate the customer experience, improve productivity and power growth for SMBs." Document Systems will become part of Xerox Business Solutions, aligned to the XBS West region, and provide Xerox solutions targeted at SMBs that support collaboration, communication, remote IT support, security and automation. Terms of the transaction were not disclosed.

14:17 EDT PlayStation's Hulst says 'God of War' sequel not coming out this year - In a PlayStation blog Q&A, Sony PlayStation Studios head Hermen Hulst confirmed that upcoming PS5 game "Horizon Forbidden West" is on track for release this holiday season, while the sequel to 2018's "God of War" is being delayed to next year. Hulst also said that the new "Horizon," "God of War," and "Gran Turismo 7" will all be cross-platform, meaning they will release both for PlayStation 4 and PlayStation 5. Reference Link

13:53 EDT North American rail traffic rose 28.1% in week ended May 29, AAR says - The Association of American Railroads, AAR reported U.S. rail traffic for the week ending May 29, as well as volumes for May. U.S. railroads originated 964,356 carloads in May 2021, up 30.4%, or 224,623 carloads, from May 2020. U.S. railroads also originated 1,151,824 containers and trailers in May, up 26.2%, or 238,927 units, from the same month last year. Combined U.S. carload and intermodal originations in May 2021 were 2,116,180, up 28%, or 463,550 carloads and intermodal units from May 2020."U.S. rail volumes in May 2021 were encouraging. Total carloads were the most for any month since October 2019 on a weekly average basis," said AAR Senior Vice President John T. Gray. "In May, 18 of the 20 carload categories we track had carload gains over May 2020, while 12 of the 20 had gains over May 2019. Meanwhile, intermodal just had the best January to May period ever for U.S. railroads. Railroads hope to build on these gains in the months ahead as they help the economy return to strong, sustainable growth."Total U.S. weekly rail traffic was 530,225 carloads and intermodal units, up 34% compared with the same week last year.Total carloads for the week ending May 29 were 243,304 carloads, up 35.3% compared with the same week in 2020, while U.S. weekly intermodal volume was 286,921 containers and trailers, up 33% compared to 2020. North American rail volume for the week ending May 29, 2021, on 12 reporting U.S., Canadian and Mexican railroads totaled 341,112 carloads, up 28.1% compared with the same week last year, and 376,337 intermodal units, up 28.1% compared with last year. Total combined weekly rail traffic in North America was 717,449 carloads and intermodal units, up 28.1%. North American rail volume for the first 21 weeks of 2021 was 14,727,824 carloads and intermodal units, up 12.1% compared with 2020. Publicly traded companies in the space include ArcBest (ARCB), J.B. Hunt (JBHT), Knight-Swift (KNX), Old Dominion (ODFL), Swift Transportation (SWFT) and Werner (WERN). Reference Link

13:21 EDT Google to allow U.S. ads for cryptocurrency exchanges, wallets as of August - In a support page post, Google stated in part: "In August 2021, Google will update the Financial products and services policy to clarify the scope and requirements to allow the advertisement of cryptocurrency related business and services. Beginning August 3, advertisers offering Cryptocurrency Exchanges and Wallets targeting the United States may advertise those products and services when they meet the following requirements and are certified by Google... All prior Cryptocurrency Exchange certifications will be revoked on August 3, 2021. Advertisers must request new Cryptocurrency Exchanges and Wallets certification with Google when the application form is published on July 8, 2021." Reference Link

13:10 EDT Mox Reports has small AMC position, says short squeeze 'just beginning' - Richard Pearson of Mox Reports said via Twitter, "Yes. I have small long posn in $AMC which I bot a few weeks ago. I think the #Shortsqueeze in $AMC is only just beginning. I will never understand why so many ppl keep stepping on the same rake by going short these based on valuation, same as $GME at $20 (and $GME at $200 btw)." Reference Link

12:58 EDT Facebook says Login Connect in closed beta

12:54 EDT FBI reports 3.22M NICS firearm background checks in May - The FBI reported that there were 3,222,105 firearm background checks initiated through the NICS system in May 2021. This compares to 3,091,455 checks in May of 2020 and 3,514,070 checks in April 2021. Companies in the firearm space include Sturm, Ruger (RGR), Smith & Wesson Brands (SWBI), and Vista Outdoor (VSTO). Reference Link

12:32 EDT Facebook says Messenger API for Instagram now available to all developers - Says developers can now build "robust" tools for businesses through Instagram. Says developers can now give businesses the ability to manage communications in one place.

12:29 EDT AMC Entertainment halts for volatility after jumping 93% to $61.71

12:26 EDT AMC Entertainment trading halted, volatility trading pause

12:16 EDT Facebook to launch Researcher API - Says launching new API specifically for research community. Says Researcher API provides real-time access to Pages, Groups, Events, and Post-level U.S. data in a secure manner. Comments taken from Facebook's F8 Refresh online event.

12:04 EDT Microchip: Demand environment 'really, really high' right now - CFO James Bjornholt says the demand environment is "really, really high," with orders outpacing supply, adding that the company is "playing catch up every day." Comments taken from the Cowen TMT Conference.

12:00 EDT Natuzzi falls -11.6% - Natuzzi is down -11.6%, or -$2.65 to $20.10.

12:00 EDT Express rises 16.8% - Express is up 16.8%, or 80c to $5.57.

12:00 EDT AMC Entertainment rises 37.7% - AMC Entertainment is up 37.7%, or $12.08 to $44.12.

11:31 EDT Arizona Attorney General settles civil rights cases with Uber, DoorDash - Arizona Attorney General Mark Brnovich announced that his office settled civil rights cases involving Uber Eats (UBER), Postmates, and DoorDash (DASH) regarding allegations of discrimination based on race. The companies can no longer offer price distinctions based on a person's race, Brnovich said in a statement. Pursuant to the settlement agreements, the companies will not offer financial incentives, advertise, provide any delivery fee discounts, or price-related discounts to customers in Arizona based on a restaurant owner's race, color, religion, sex, national origin, or ancestry. Reference Link

11:09 EDT Crocs announces collaboration with DJ and producer Diplo - Crocs announced its official collaboration with artist, DJ and producer Diplo, the "Diplo X Crocs" partnership with a "special, first-of-its-kind two-style release featuring unique, multi-tone takes" on the Classic Clog and new Classic Crocs Sandal with custom Jibbitz charms. The limited-edition collaboration will be available on June 8 beginning at 12:00 p.m. ET. The Crocs X Diplo Classic Clog, available for $69.99 and Diplo X Crocs Classic Sandal, available for $49.99 will be sold exclusively on www.crocs.com, the company noted.

10:35 EDT Bed Bath & Beyond up 7% after revealing next wave of owned brands - Shares of Bed Bath & Beyond are up $1.94, or 7%, to $29.20 in morning trading after the company earlier announced that it will launch three new owned brands this quarter, stating that it is "continuing the company's execution of its biggest product assortment change in a generation to rebuild its authority in the $180 billion home market." With the launch of the new owned brands in the coming weeks, the company will have launched six owned brands in five months - which is ahead of its previously announced six-month timetable and comes "in advance of the important Back to College shopping season," Bed Bath & Beyond stated. The owned brands that will launch in the market in the coming weeks and be available only at Bed Bath & Beyond include "Our Table," a new line of modern kitchen and dining wares, "Wild Sage," which the company calls a "youthful, eclectic collection of stylish and free-spirited pieces for the home," and "Squared Away," a new line of storage, organization, and cleaning solutions for the home. Mark Tritton, President and CEO of Bed Bath & Beyond, said, "I am pleased that we are ahead of schedule in delivering our Owned Brands plan, launching product assortments strategically sequenced to cover our core destination categories of bed, bath, kitchen & dining, indoor decor and storage & organization. Together with the company's first opening-price-point Owned Brand, we are helping customers unlock the magic in every room while strengthening our leadership in the home market."

10:28 EDT GE Aviation announces plans for new manufacturing operations in Ohio - GE Aviation announced that the company recently broke ground on its new lean engine component manufacturing facility for both civil, military aviation and aero derivative applications. The facility will be built on 53 acres in the Miami Valley Research Park located at 4230 Research Blvd in Beavercreek, Ohio. The 280,000 square foot facility is expected to be completed by the first quarter of 2022 and fully operational by the end of 2022. The new facility will optimize manufacturing operations and advanced technology development into one facility, combining operations from seven buildings into one. GE currently has approximately 400 hourly and salaried employees who will be located at the new facility. "This project is setting the stage for the future of this business by allowing us to serve our customers better due to lean productivity and an increase in flexibility as a workforce, that will improve and maintain our competitiveness for the future," said Kristie West, general manager, GE Aviation.

10:18 EDT Blue Bird expects electric bus sales to accelerate through rest of 2021 - School bus manufacturer Blue Bird Corporation announced that during an annual dealer meeting in late May the company reported the "milestone of 500 electric-powered school buses delivered or on order." Blue Bird added in a press release regarding its milestone: "As the only school bus manufacturer that produces and sells all three school-bus body configurations in EV, Blue Bird expects its electric bus sales to accelerate through the rest of 2021."

10:09 EDT Cornerstone OnDemand jumps after Clearlake discloses activist stake - Shares of Cornerstone OnDemand are jumping after Jose Feliciano's Clearlake Capital Group disclosed an 8.3% stake in the company, which represents over 5.5M shares. The filing with the SEC allows for activism. Clearlake initially acquired the shares for investment purposes, but said it changed its intent and is "currently evaluating alternatives for their current investment and potential future investment" in Cornerstone. Towards that end, Clearlake has engaged in communications with members of management and the board for the "review and evaluation of strategic alternatives, opportunities to increase shareholder value, Issuer operations, governance and control." Clearlake Capital added that it may seek to enter into a non-disclosure agreement. Shares of Cornerstone OnDemand are up 5%, or $2.20, to $46.17 in morning trading.

10:00 EDT KE Holdings falls -6.7% - KE Holdings is down -6.7%, or -$3.63 to $50.48.

10:00 EDT Medallia rises 13.9% - Medallia is up 13.9%, or $3.50 to $28.57.

10:00 EDT Pennsylvania REIT rises 24.9% - Pennsylvania REIT is up 24.9%, or 64c to $3.21.

09:50 EDT Fresh Del Monte partners with I Squared Capital for digital era - Fresh Del Monte Produce announced its partnership with I Squared Capital, an independent global infrastructure investment manager focusing on energy, utilities, digital infrastructure, transport, and social infrastructure in the Americas, Europe and Asia. By creating this partnership and investing in the I Squared Global InfraTech Fund, Fresh Del Monte takes the next step in transforming into a digital-forward company with technology-enabled capabilities to further enhance its products and customer satisfaction. The fund invests in innovative growth-stage companies applying technology in various infrastructure sectors, including logistics, supply chain, and agriculture. Fresh Del Monte and I Squared Capital will share investment prospects, seek to co-invest in certain deals, and offer general support by sharing research and learnings in certain technology fields, including Internet of Things, energy storage, and vertical farming.

09:47 EDT Imax falls -5.2% - Imax is down -5.2%, or -$1.16 to $21.11.

09:47 EDT Medallia rises 9.3% - Medallia is up 9.3%, or $2.33 to $27.40.

09:47 EDT AMC Entertainment rises 13.5% - AMC Entertainment is up 13.5%, or $4.33 to $36.37.

09:44 EDT Pitney Bowes expands locker portfolio with launch of ParcelPoint Smart Lockers - Pitney Bowes announced the expansion of its lockers portfolio with the launch of ParcelPoint Smart Lockers, "a new suite of robust, secure contactless locker solutions unique to Pitney Bowes. Ideal for organizations planning the safe reopening of offices, college campuses and government agencies, these smart lockers give organizations the confidence that every package and asset moving across a location will be delivered safely and securely. Powered by proprietary SaaS software, organizations can remotely manage a single locker or a fleet of lockers across locations, backed up with unrivalled local Pitney Bowes service, support and detailed analytics," the company said. Kerry Caylor, Vice President, SendTech Parcel and Locker Innovation, Pitney Bowes said, "The global automated parcel locker market is expected to exceed $1.4 billion by 2027, driven by organizations looking for ways to manage the exponential growth in ecommerce and parcel volume. Pitney Bowes ParcelPoint Smart Lockers with powerful SaaS software make it easy for organizations to automate, streamline and digitize their parcel and mail management and deliver a user-friendly contactless pickup experience. By providing the both pre-configured and customized options, we're giving organizations the choice and flexibility to select the smart locker solution that exactly matches their requirements and the needs of the clients they serve."

09:39 EDT ADM Ventures collaborates with Genesis Consortium to support startups - ADM Ventures, the corporate venture capital arm of ADM, announced its collaboration with the Genesis Consortium, founded by Silicon Valley-based investors SOSV and Mayfield Fund. "Genesis is a global alliance of venture capital firms and corporations dedicated to supporting startups that leverage biology to promote human and planetary health. SOSV is the parent company of IndieBio, a leading startup accelerator and early-stage investor for biology-centered startups worldwide," the company said. "ADM and the Genesis Consortium share a common focus at the intersection of sustainability, nutrition, and health and wellness. We view the Genesis Consortium as a conduit through which ADM can collaborate with emerging players in the industry to bring to market new, natural products that simultaneously meet consumer demands and solve pressing global challenges," said Ian Pinner, ADM's Chief Strategy and Innovation Officer. "Innovative startups are unlocking scientific advancements by leveraging biology and fermentation to produce nutritional, health and wellness, and bio-material solutions sustainably and cost-competitively. ADM is focused on leveraging its deep expertise in fermentation to accelerate the commercialization of these game-changing innovations."

09:37 EDT Ameriprise Financial applies for a state industrial bank charter - Ameriprise Financial has filed an application to convert Ameriprise Bank, FSB to a state-chartered industrial bank regulated by the Utah Department of Financial Institutions and the Federal Deposit Insurance Corporation. The company is also filing an application to transition the FSB's personal trust services business to a new limited purpose national trust bank regulated by the Office of the Comptroller of the Currency. "The changes do not impact the company's long-term growth strategy for the bank and enables Ameriprise to continue offering its strong lineup of banking solutions, including deposits, credit cards, mortgages and securities-based lending to its wealth management clients without interruption. Converting to an IB charter will help the company align capital frameworks across its businesses to compete more effectively and efficiently," the company said.

09:34 EDT PAVmed launches digital health company Veris Health - PAVmed announced the launch of a new subsidiary, digital health company Veris Health, which acquired Oncodisc, a digital health company with tools to improve personalized cancer care through remote patient monitoring. Oncodisc was founded by experienced physician entrepreneurs, James Mitchell, M.D., who joins Veris as its full-time Chief Medical Officer, and Andrew Thoreson, M.D., who will serve as a Veris consultant. Oncodisc's core technologies include the first intelligent implantable vascular access port with biologic sensors and wireless communication, combined with an oncologist-designed remote digital healthcare platform that provides patients and physicians with new tools to improve outcomes and optimize the delivery of cost-effective care through remote monitoring and data analytics. Its groundbreaking vascular access port contains biologic sensors capable of generating continuous data on key physiologic parameters known to predict adverse outcomes in cancer patients undergoing treatment. Wireless communication to the patient's smartphone and its cloud-based digital healthcare platform efficiently and effectively delivers actionable real time data to patients and physicians. The technologies are the subject of multiple patent applications and one allowed patent awaiting final issuance. Veris is targeting FDA 510(k) clearance of the intelligent implantable vascular access port and launch of the remote digital healthcare platform for H2-2022. The planned Veris business model seeks to generate 100% recurring revenue through oncology practice and hospital-based subscriptions. These entities would purchase seats on the platform and pay a monthly remote monitoring charge to drive revenues from remote patient monitoring and device implantation under existing CPT codes, as well as established CMS Oncology Care Model bonuses and CMS Quality Reporting Program incentives. Veris also anticipates strong demand for its intelligent implantable vascular access port and remote monitoring platform from oncology biotherapeutic companies to support clinical trials of their novel immunotherapy and chemotherapy agents with continuous physiologic data and transformative analytics. PAVmed formed Veris Health Inc., a Delaware Corporation, as a wholly owned subsidiary, which in turn entered into a Stock Purchase Agreement to acquire 100% of the outstanding shares of Oncodisc Inc. from Oncodisc Holdings LLC, including all of Oncodisc's intellectual property, hardware, and software assets. In exchange, PAVmed granted Oncodisc Holdings LLC a 19.6% equity interest in Veris and provided $155,250 in cash to pay off two Oncodisc convertible notes. No additional cash consideration or PAVmed stock consideration was provided. A Shareholder Agreement between the parties provides additional terms and conditions concerning certain regulatory and commercial milestones, anti-dilution protection and other customary provisions. PAVmed will manage Veris through a Management Services Agreement until such time that the Veris Board of Directors decides to engage a dedicated management team and will finance its operations through intercompany advances until Veris decides to raise its own capital. Mitchell and Thoreson have entered into employment and consulting agreements, respectively, which include stringent intellectual property assignment and non-compete provisions.

09:26 EDT Zoom Video CFO net dollar expansion rate to remain above 130% for few quarters - In its earnings conference call yesterday, Zoom Video CFO Kelly Steckelberg stated: "Our net dollar expansion rate for customers with more than 10 employees exceeded 130% for the 12th consecutive quarter as customers acquired more Zoom Meetings, Rooms, Webinars and Phone products. For this customer subset, we expect the net dollar expansion rate to remain above 130% for the next few quarters. For customers with 10 or fewer employees, which are not included in its net dollar expansion metric, we expect that cohort to be lower than FY '21 as more volatile - and more volatile as economies continue to reopen."

09:21 EDT Cheesecake Factory provides business update on restaurant sales - The Cheesecake Factory Incorporated provided a business update in advance of the company's participation at two upcoming investor conferences. Fiscal 2021 second quarter-to-date through May 31st comparable sales for The Cheesecake Factory restaurants increased approximately 196% year-over-year and 7% relative to the same period in fiscal 2019, supported by approximately one-third off-premise sales mix. Based on average weekly sales quarter-to-date of approximately $226,500, this equates to approximately $11.8M on average, per unit on an annualized basis. As of today, nearly all of the company's restaurants across its concepts, including 206 Cheesecake Factory locations, are operating with reopened indoor dining rooms with limited capacity in accordance with local mandates and social distancing protocols. On average, Cheesecake Factory restaurants with reopened dining rooms are operating at approximately 70% indoor capacity and approximately 75% total on-premise capacity including patios. One Cheesecake Factory location is operating an off-premise only model and two locations across the Company's concepts are currently closed with plans to reopen next week. One new Flower Child location opened in Atlanta last month.

09:20 EDT Butterfly Network second-generation iQ+ approved in Canada - Butterfly Network announced that its second-generation iQ+ has been approved for a Class III Medical Device License in Canada. The iQ+ features the world's only Ultrasound-on-Chip technology, with several hardware and software advances designed to improve usability and care delivery. "We are excited that the Butterfly iQ+ will now be available for purchase by Canadian medical professionals," said Todd Fruchterman, MD, Ph.D., President and Chief Executive Officer of Butterfly Network. "Thousands of new practitioners and millions of patients will now have access to a transformative advanced assessment tool that can deliver valuable insights that enable more informed clinical decisions at the point of care." With Canada's approval, Butterfly iQ+ is now available in 20 countries across the world.

09:18 EDT Brose enrolls in in DTE's MIGreenPower voluntary renewable energy program - DTE Energy and Brose today announced Brose's enrollment in DTE's MIGreenPower voluntary renewable energy program. Brose's clean energy purchase of 11,445 megawatt hours annually will avoid 81,110 metric tons of CO2 over the company's 10-year contract. This has the environmental benefit equal to the carbon sequestered by 99,000 acres of U.S. forests in a year.* Brose's MIGreenPower commitment will be sourced from new clean energy projects that are currently under development and scheduled to come online in early 2023.

09:17 EDT Booz Allen awarded 5-year, $674M contract by GSA - Booz Allen Hamilton was awarded a 5-year, $674M contract by the General Services Administration, or GSA, to maintain and support the exponential growth of the Department of Defense's Advana data analytics platform to improve decision making across the organization. Advana, led by the Office of the Under Secretary of Defense, integrates hundreds of business systems across the DoD - from financial and medical data to personnel and logistics - to make data widely accessible, understandable and usable. The platform is currently used by over 20,000 users spanning 42 DoD organizations in order to meet critical mission and business challenges.

09:15 EDT HUMBL enter strategic collaboration with Athletes First - HUMBL announced it has retained Athletes First as a strategic consultant to focus on the development of new business verticals in such areas as non-fungible tokens, digital media and ticketing. Athletes First will support HUMBL in delivering elite, white-glove service for a select group of A-list sports and entertainment talent, with an initial focus on creating highly-curated NFT galleries alongside Emmy-nominated creative house Goat Farm Media. Athletes First will also provide HUMBL with introductions in the ticketing industry, marketing and promotional support, and access to Athletes First's digital content library.

09:15 EDT NortonLifeLock announces the launch of Norton Crypto - NortonLifeLock announced the launch of Norton Crypto, a new feature designed to enable consumers to safely and easily mine cryptocurrency through its trusted Norton 360 platform. Starting tomorrow, select Norton 360 customers in Norton's early adopter program will be invited to mine for Ethereum. "As the crypto economy continues to become a more important part of our customers' lives, we want to empower them to mine cryptocurrency with Norton, a brand they trust," said Vincent Pilette, CEO of NortonLifeLock. "Norton Crypto is yet another innovative example of how we are expanding our Cyber Safety platform to protect our customers' ever-evolving digital lives."

09:14 EDT Malta Police deploy Motorola Solutions' body-worn cameras - Motorola Solutions announced that Malta Police Force has deployed Motorola Solutions' VB400 body-worn cameras to all frontline officers across the Republic of Malta. The roll out is part of Malta Police Force's transformation strategy which aims to modernize the police force while increasing trust and transparency with the community. The five-year service contract for the comprehensive video solution includes evidence management software to process captured video footage securely and the new Holster Aware feature which allows the camera to automatically start recording if a weapon is unholstered.

09:14 EDT Zivo Bioscience announces uplisting to Nasdaq - Zivo Bioscience announced the closing of its previously announced underwritten public offering of 2,760,000 units at a price to the public of $5.00 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $5.50. The common stock and warrants were immediately separable and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on May 28, 2021, under the symbols "ZIVO" and "ZIVOW," respectively. ZIVO received gross proceeds of approximately $13.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All share numbers and pricing information in this press release reflect the Company's previously announced 1-for-80 reverse stock split of its issued and outstanding common stock, which became effective at 12:01 a.m., Eastern Time, on May 28, 2021.

09:12 EDT Super Micro Computer introduces Rack Scale Plug and Play Solutions - Super Micro Computer is introducing Rack Scale Plug and Play Solutions, turn-key, pre-defined, pre-tested, and validated rack-level solutions for advanced data center environments. Supermicro offers complete racks pre-configured with servers, storage, networking equipment, cabling, software configurations, and management infrastructure designed and built by a global in-house staff. Supermicro works directly with customers on the system architecture, workload demands, and final solution validation. The Supermicro rack level designs are initially targeted for Cloud, AI, 5G/Edge, and High Performance Computing. CEO Charles Liang presented Rack Scale Plug and Play Solutions at Computex Taipei on June 2.

09:12 EDT Remote Picture Labs partners with Avid to 'transform' post production editing - Avid announced a multi-year partnership with Remote Picture Labs a leading provider of remote editing solutions for the Hollywood film and television industry. This agreement enables RPL to offer a virtual film and television post production solution that allows editors, assistant editors and producers to collaborate from anywhere using Avid's Media Composer software and Avid NEXIS storage products offered as a service to its customers. RPL has shifted its business model to address the changing landscape as media companies gravitate toward "as-a-service" offerings to support an increasingly distributed workforce, moving from perpetual licenses to subscription with Avid. Originally developed so that edit teams could work during the COVID-19 pandemic, the RPL solution provides all the system performance and functionality of traditional Avid workstations. Each virtualized client runs on RPL's high-performance private cloud in a robust, secure environment that possesses the same picture and audio quality and throughput found in on-premises edit bays. This continuity enables the seamless transition to a remote, collaborative environment, with content security assured through multi-factor authentication and AES-256 encryption. "A primary consideration from the outset was to let edit teams use their existing media and projects," said Erik Beauchamp, Chief Technical Officer at Remote Picture Labs.

09:11 EDT Philips, Akumin partner to advance radiology performance - Royal Philips (PHG_ and Akumin (AKU) announced a strategic collaboration to deploy Philips' new Radiology Operations Command Center across Akumin's outpatient imaging centers and co-create clinical standards for Akumin's MR and CT imaging modalities. Designed to centralize, virtualize, and standardize network-wide imaging operations while facilitating secure remote access, Philips' vendor-agnostic command center broadens the scope of collaboration and expertise sharing between technologists, radiologists and imaging operations teams across multiple sites capabilities that fit perfectly into Akumin's networked imaging center model. Akumin, which currently operates over 130 outpatient imaging centers across seven U.S. states, is Philips' first large-scale commercial Radiology Operations Command Center customer in North America.

09:10 EDT Steris completes Cantel Medical acquisition - Steris announced that it has completed the previously announced acquisition of Cantel Medical, a global provider of infection prevention products and services to endoscopy, dental, dialysis and life sciences Customers. "We are pleased to announce the closing of the Cantel Medical acquisition, which will complement and extend STERIS's product and service offerings, global reach and Customers," said Walt Rosebrough, President and Chief Executive Officer of STERIS. "We welcome Cantel people to the STERIS team, and look forward to working together to create more value for our Customers, our people, and our shareholders." Guggenheim Securities served as financial advisor to STERIS and Jones Day as legal counsel. JPMorgan Chase Bank, N.A., served as sole lead arranger and bookrunner in respect of certain financing. Centerview Partners LLC served as exclusive financial advisor to Cantel and Wachtell, Lipton, Rosen & Katz as legal counsel.

09:08 EDT Broadcom launches Adaptive Protection capability - Broadcom announced the launch of Adaptive Protection, an advanced capability as part of the Symantec Endpoint Security solution. Leveraging the latest advanced machine learning techniques built on decades of Symantec endpoint security experience, Adaptive Protection delivers enhanced security that is automated and customized for each customer's environment while ensuring zero impact to productivity. Adaptive Protection effectively enables enterprises to stay ahead of cyber attacks and stop breaches before they happen.

09:06 EDT Inuvo announce expansion of its IntentKey AI platform for Canadian market - Inuvo announces the expansion of its IntentKey AI platform for advertising into the Canadian market where advertisers can now take advantage of a technology that has consistently delivered market beating performance results. Rich Howe, Chief Executive Officer of Inuvo, commented, "The value proposition for Canadian companies is strong: we can serve both their domestic and American advertising objectives; we can beat current providers performance results; we can run it all for them or they can use it in-house; and we are future proof as our technology is not dependent on third-party data or cookies because it was designed to uncover signals of intent that define the why that drives a product/service purchase, not the who that is behind that purchase. In the new cookieless world, who will become irrelevant as targeting predefined users or personas becomes increasingly difficult."

09:06 EDT STMicroelectronics, MetaLenz partner for optical sensing - STMicroelectronics and Metalenz announced a co-development and license agreement that will see ST develop manufacturing processes for Metalenz's meta-optics technology for next-generation smartphones, consumer devices, healthcare, and automotive applications. Metalenz is a spin-out of the group of Federico Capasso at Harvard University, where the technology was invented. This breakthrough technology is expected to be ready for mass production by the end of this year. Metalenz's multifunctional meta-surface optics enable new forms of sensing for the next generation of smartphones and other consumer devices, as well as healthcare and automotive applications.

09:06 EDT Indigo Natural Resources confirms merger with Southwestern Energy - Indigo Natural Resources announced that it has entered into a definitive merger agreement with Southwestern Energy Company, under which Southwestern will acquire Indigo for approximately $2.7B. The total consideration of $2.7B will be comprised of $400M in cash, approximately $1.6B in SWN common stock and $700M in aggregate principal amount of assumed 5.375% Senior Notes due 2029 of Indigo. This release constitutes the public announcement of the intention of Indigo to effect a Change of Control, as defined under the indenture governing the Notes. The transaction was unanimously approved by each of Southwestern Energy's and Indigo's board of directors. The transaction is expected to close early in the fourth quarter, subject to regulatory approvals, customary closing conditions and the approval by Southwestern Energy's shareholders.

09:04 EDT Caterpillar working to minimize impact of shortages on customers

09:04 EDT Carlyle Group makes strategic investment in Neogov - Carlyle Group and existing investor Warburg Pincus, a global growth investor, have made a "significant" investment in Neogov, a provider of public sector human capital management and policy management software. Terms of the transaction were not disclosed. Founded in 2000, Neogov provides a software-as-a-service human capital management platform to automate and streamline the employee lifecycle for state and local government, education, public safety, and other public sector customers. Neogov's software is designed specifically for the unique requirements of these complex and regulated end-markets and serves more than 6,500 organizations. The new investment from Carlyle Group and Warburg Pincus will allow Neogov to capitalize on a number of organic and inorganic growth opportunities, including investing in Neogov's operations and go-to-market teams. In addition to expansion into new markets, Neogov will continue to serve as a platform for meaningful M&A in the broader government technology landscape. Equity capital for Carlyle's investment will come from Carlyle Partners VII, an $18.5B fund that makes majority and strategic minority investments primarily in the U.S.

09:04 EDT Digital Colony completes acquisition of Boingo Wireless - Boingo Wireless and an affiliate of Digital Colony Management announced that funds managed by affiliates of Digital Colony completed their acquisition of Boingo. The transaction, which was previously announced on March 1, 2021, valued Boingo at approximately $854M, including the assumption of $199M of Boingo's net debt obligations. Under the terms of the merger agreement, which was approved by Boingo's stockholders at a special meeting held on June 1, 2021, Boingo stockholders will receive $14 in cash per share of Boingo's common stock. As a result of the completion of the transaction, Boingo is now a privately-held company and its common stock no longer trades on the NASDAQ. "With the adoption of 5G, Wi-Fi 6 and CBRS, demand for converged indoor networks will continue to dramatically increase over the next decade. As a leading indoor digital infrastructure provider serving the connectivity needs of essential properties, Boingo is ideally positioned to build on its market leadership and capitalize on this growth opportunity," said Marc Ganzi, Colony Capital President and CEO of Colony Capital and CEO of Digital Colony. "This investment represents a unique platform that will only further be enhanced by Digital Colony's strong operational capabilities, industry relationships, and access to capital. We look forward to working with Mike and the entire Boingo team as they continue to advance its business strategy in developing and deploying reliable networks and serving their diverse set of high-quality customers."

09:03 EDT Caterpillar: Demand increasing 'quite strongly'

09:03 EDT Hyundai Motor America reports total May sales of 90,017 units, up 56% y/y - Hyundai Motor America reported total May sales of 90,017 units, a 56% increase compared with May 2020. Hyundai again set an all-time monthly sales record for the third consecutive month. Fleet sales increased 95%, representing 6% of total volume. May was also the best retail month ever, with 84,351 retail sales, up 54%. Retail sales rose for the entire lineup with SUVs (+34%), cars (+105%) and eco-friendly vehicles (+887%), all growing substantially. Eco-friendly vehicles also accounted for 11% of the retail volume.

09:02 EDT Methanex releases 2020 Sustainability Report - Methanex Corporation released its 2020 Sustainability Report to share its progress on the material environmental, social and governance topics of most importance to the company's business and stakeholders. Methanex has reported on its sustainability performance since 1997 and this year's report provides greater transparency and comparability by aligning its disclosures with the Sustainability Accounting Standards Board standards and some elements of the Task Force on Climate-related Financial Disclosures and Global Reporting Initiative. The 2020 Sustainability Report describes Methanex's actions to reduce greenhouse gas emissions from operations, outlines how the company manages climate-related opportunities and risks for its business, and identifies the technology solutions it is exploring to further reduce emissions from operations. Report highlights in these areas include: Ordering eight new methanol dual-fuel vessels for the Waterfront Shipping fleet, the world's largest dedicated fleet of methanol ocean tankers - 60 per cent of which will be powered by methanol fuel technology by 2023. When methanol is used as a marine fuel, it can result in an 80 per cent reduction in nitrogen oxides, 85 per cent reduction in particulate matter, 99 per cent reduction in sulphur oxides and 15 per cent lower carbon dioxide emissions during combustion compared to traditional marine fuel. Obtaining International Sustainability & Carbon Certification for the biomethanol produced at two of the Geismar, Louisiana, plants using biomethane from municipal solid waste and other sources. This certification will enable Methanex to sell biomethanol to European customers under the Renewable Energy Directive, which sets targets for energy from renewable sources for fuel suppliers. Producing more than 59,000 tonnes of low-carbon methanol at the Medicine Hat, Alberta, plant by using carbon dioxide captured from a neighbouring industrial facility that would otherwise be released to the atmosphere.

08:59 EDT Conduent announces contract from New Hampshire Department of Health - Conduent announced a contract from the New Hampshire Department of Health and Human Services DHHS, to provide Medicaid beneficiaries in the state with improved, secure access to their personal health information, enabling them to make more informed healthcare decisions. The company's solution will improve how information is exchanged between payers, providers and patients, as well as support efficient care coordination. Through a web portal developed by Conduent, beneficiaries will have the ability to locate healthcare and pharmacy providers in their network, as well as seamlessly and securely review their information and share it with various providers. The contract also brings New Hampshire into compliance with the Interoperability and Patient Access Final Rule, a federal regulation put into effect by the Centers for Medicare and Medicaid Services. The rule, finalized in 2020, is expected to have a major impact nationally on the future of healthcare, making health information more easily available to patients and allowing them to safely share their data. The contract marks an expansion of Conduent's support for NH DHHS, a client since 2013. The company currently provides the department with claims processing and provider services for New Hampshire's Medicaid program, as well as management of its Medicaid Management Information System (MMIS), which processes more than 15 million claims annually.

08:58 EDT Orbit International to recommence stock repurchase program - Orbit International announced that its Board of Directors has authorized the Company to recommence its share repurchase program with an approval to purchase up to $600,000 of its common shares. The $600,000 program would normally be reduced by the amount of any cash dividend payments made to its shareholders; however, the Board did not commit to recommencing its quarterly cash dividend, which it suspended along with its share repurchase program in May 2020 and April 2020, respectively, due to the COVID-19 pandemic. The Company currently has bank approval for up to $600,000 of share repurchases and cash dividend payments under its current lending agreement and is in the process of increasing the amount to $850,000 in connection with the extension of its line of credit agreement with its primary lender. The Company expects to have the extension completed by the end of the current second quarter.

08:57 EDT Midwest Energy Emissions announces debt repayment agreement - Midwest Energy Emissions announced that it has entered into a debt repayment agreement with AC Midwest Energy, an affiliate of Alterna Capital Partners, a registered investment advisor, which will repay all existing secured and unsecured debt obligations presently held by Alterna. Pursuant to the Debt Repayment and Exchange Agreement with Alterna, ME2C Environmental shall repay the existing $0.3 million secured note outstanding in cash as well as the existing $13.2 million principal amount outstanding under an unsecured note through a combination of cash and stock. Alterna is also entitled to a certain non-recourse profit share under the unsecured note which will be satisfied also through a combination of cash and stock. The completion of the transaction described herein is subject to various closing conditions.

08:56 EDT CareTrust approves transfer of operations in four facilities to Ensign Group - CareTrust REIT (CTRE) confirmed that it has approved a request from longtime tenant Five Oaks Healthcare, L.L.C. to transfer the operations in four of its CareTrust-owned skilled nursing facilities to affiliates of The Ensign Group, Inc. (ENSG), effective June 1, 2021. The four Washington state facilities will be added to an existing long-term, triple-net master lease between CareTrust and Ensign. The master lease, one of eight legacy multi-facility master leases between CareTrust and Ensign operating affiliates, was also amended to extend its remaining primary lease term by ten years to 2036.

08:54 EDT Pioneer Power board of directors declare one-time cash dividend of 12c per share - On June 1, 2021, the company's Board of Directors declared a one-time special cash dividend of 12c per common share. The dividend will be paid on July 7, 2021 to shareholders of record as of June 22, 2021. The dividend will be funded with surplus cash on the company's balance sheet.

08:53 EDT Vystar Corp partners with Nothing in the Air for RxAir - Vystar Corporation's RxAir division has joined forces with a powerful new ally, Nothing in the Air to market and distribute the RxAir ultraviolet light air purifier product line. NITA expands Vystar's network of licensed distributors and will focus primarily on marketing online and via television in select markets. On June 3rd, NITA will roll out its first RxAir advertising campaign on ROKU, TV commercials during PBS healthcare programming, as well as an online campaign with RxAir customer testimonials.

08:51 EDT Eros STX Global expands existing partnership with Xfinite's Mzaalo platform - Eros Now, a leading South Asian entertainment platform owned by Eros STX Global Corporation, announced details of its amended partnership with Mzaalo, a gamified video streaming service owned by Xfinite Global. "The partnership further establishes Eros Now's footprint in advertising video on-demand, a still-developing segment of the India streaming market that has significant growth potential, while allowing Eros Now to continue building its core subscription video on-demand service. This agreement, given Xfinite's innovative business model, also provides ErosSTX with positive optionality on the potential growth in digital assets and blockchain technology," the company said. ErosSTX is licensing the majority of the existing Eros Now content library to Xfinite on an exclusive basis for global AVOD monetization. The content excluded from this licensing agreement includes content licensed from third-parties with sub-licensing restrictions, and English-language content, including STX content. This agreement does not preclude Eros Now from launching its planned English-language service, Eros Now Prime, or from licensing content to other SVOD services. The Company believes this AVOD initiative will allow Eros Now to efficiently monetise a large and engaged userbase. The AVOD platform will play a key role in Eros Now's future content strategy and facilitate new release windows, which will give consumers more choices and flexibility. Eros Now currently plans to offer premium original titles and movies in the first window to Eros Now paying subscribers. Under the amended and restated agreement with Mzaalo, ErosSTX is entitled to a minimum guaranteed cash payment of $42M over the remaining four-year license term, ending December 2024. ErosSTX has already received $18M in minimum guaranteed payments under the original contract that started in 2018. Additionally, ErosSTX will receive a 50% share of any Mzaalo revenue generated above the minimum guarantee. Lastly, ErosSTX will receive 400 million XET Digital Tokens in exchange for access to Eros Now's database of registered users, which totalled 224M as of March 31, 2021.

08:49 EDT Radius says FDA requirements make abaloparatide generic 'more challenging' - FDA Guidance on Synthetic Peptides: On May 19, 2021 the FDA published updated guidance and requirements for synthetic peptides and what would be required in any generic filings and advancement. Radius views this new guidance as meaningful in assessing the probability of a generic synthetic peptide being filed and gaining market entry. In sum, the Company views these newly communicated FDA requirements as making it significantly more challenging to advance and develop a generic version of abaloparatide. The key components of the new FDA guidelines include: Recombinantly sourced peptides cannot be approved in an ANDA and must be submitted in a 505(b)(2) NDA; Explicit references to the potential for significant consequences if anti-drug antibodies cross-react against endogenous peptides; New impurities must be within the FDA's threshold; if greater, must be submitted as a 505(b)(2); Explicit expectation: ANDA with new impurity must evaluate immunogenicity risks prior to filing. RAD011 ASSET FDA Type C meeting for PWS will take place the week of June 14. Written minutes from the FDA meeting expected by the end of July. Post FDA discussion, expectation is to initiate a pivotal PWS trial before year end. Additional orphan indications being assessed in parallel - decisions and clarity in 2H, 2021. Multiple Advisory Board meetings completed: U.S., UK, EU for PWS plus a Psychiatry meeting. Internal team formed: clinical, pharm. science, regulatory, bio-stats, CMC, global franchise. External team established: manufacturing & supply chain, development, regulatory, advocacy/

08:47 EDT Neogen's Viroxide Super approved by EPA for U.S. distribution - Neogen's Viroxide Super disinfectant has been granted an expedited, initial registration in the U.S. by the EPA, in part to help slow the spread of the virus that causes COVID-19. Viroxide Super is a peroxygen-based powder disinfectant that offers rapid broad-spectrum disinfection as part of a comprehensive biosecurity program. The U.S. EPA's initial registration for the distribution of NEOGEN Viroxide Super joins the approvals of other global regulatory agencies for the use of the disinfectant to help in the fight against the spread of disease.

08:47 EDT SG Blocks acquires a membership interest in Atlanta, Georgia - SG Blocks announced that SGB Development, a subsidiary of SG Blocks, has acquired a membership interest to build 70,000 sq. ft of affordable housing in the Atlanta, Georgia metropolitan area to be known as "Norman Berry Village". SGB DevCorp has partnered with CMC, a New York City-based real estate development firm with national expertise, with ZT Architecture & Land Development and Community Development Consortium providing design build services. Units will be constructed at the company's SG Echo campus in Durant, Oklahoma, and shipped to Atlanta. SGB DevCorp will control the planning and construction process, netting revenue from design, manufacturing, site work, and asset ownership stake. The project will draw on the experienced leadership of local developer Shaun Belle, CMC President. The company anticipates this to be the first of many projects in which SGB DevCorp develops, designs, constructs and delivers either single family or multi-family homes, whether that be for purchase or for rent, depending on specific market need, with both affordability and quality in mind, given the nature of housing in the area.

08:44 EDT IBM expands relationship with Persistent Systems for hybrid cloud adoption - IBM announed that Persistent Systems plans to expand its relationship with IBM to help fuel open hybrid cloud adoption, core IT modernization and digital transformation for customers across the enterprise. Spanning more than 20 years, Persistent's collaboration with IBM grew from a project in security to collaborating on more than 400 shared customers. Persistent will evolve its Red Hat Center of Excellence by adding co-engineering PODs and specialized teams focused on product engineering and advanced technology skills. Persistent will continue to use IBM Security solutions like IBM Security QRadar SIEM in conjunction with its proprietary security operations centers. The company intends to onboard its Digital Banking Solution to the IBM Cloud for Financial Services. In addition, Persistent will build and deploy its Telco Network Cloud Manager solution on the IBM Cloud for Telecommunications.

08:43 EDT Teledyne FLIR launches new identiFINDER R700 backpack radiation detector - Teledyne FLIR, part of Teledyne Technologies, announced the launch of the identiFINDER R700 Backpack Radiation Detector, an advanced mobile system that offers capability for broad-area radiological monitoring missions. The company also announced that the U.S. Department of Homeland Security has placed the first order for the device as part of its Helium-3 Alternative Implementation Backpack Program. Programmed out of the Counter Weapons of Mass Destruction office, the $6.5M award spans nine months of product deliveries.

08:41 EDT Eagle Bulk Shipping acquires two Ultramax bulkcarriers for $44M - Eagle Bulk Shipping announced that it has purchased two high-specification 2015-built scrubber-fitted Ultramax bulkcarriers for total consideration of $44 million. The vessels, which will be renamed the M/V Antwerp Eagle and M/V Valencia Eagle, are of the SDARI-64 design and were constructed at Jiangsu Hantong Ship Heavy Industry Co. The Company expects to take delivery of both ships during the third quarter of 2021. These acquisitions will be funded with cash on hand, which includes equity issued under the Company's ATM program. During the month of May, Eagle issued 475,894 shares of common stock at an average price of $47.39, raising a total of $22.5 million in gross proceeds. Separately, the Company has reached an agreement to sell the M/V Tern for $9.7 million. The sale is expected to close in July, prior to the vessel's statutory drydock and requisite ballast water treatment system installation due date. Following these transactions, Eagle's fleet will total 53 ships, with an average age of 8.7 years.

08:40 EDT Zealand, Boehringer Ingelheim receive Fast Track designation for BI 456906 - Boehringer Ingelheim and Zealand Pharma announced that the US Food and Drug Administration has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis. The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis with and without diabetes. The GLP-1/glucagon compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments. It is also being investigated as a potential treatment option for adults living with diabetes and for adults living with obesity. It is part of Boehringer Ingelheim's research and development portfolio in the cardiometabolic disease areas.

08:38 EDT Evolv Technology awarded U.S. Air Force contract - Evolv Technology announced the company has been awarded a contract with the United States Air Force to identify opportunities to bolster national safety interests through the deployment of Evolv's advanced security screening systems. Through the contract, Evolv will apply its leadership in using AI, machine learning, advanced sensors, on-demand analytics and related digital technologies for next-generation touchless weapons screening and threat detection. Working with program sponsors, the company will conduct feasibility studies on how the military and other federal government organizations can improve physical security while optimizing operations and reducing costs at military bases, air terminals, air shows, special events and other locations.

08:37 EDT Osisko Development announces drilling results from Cariboo project - Osisko Development is pleased to announce drilling results from the 200,000-meter 2021 exploration and category conversion drill program campaign at its Cariboo Gold Project in central British Columbia. A total of ten diamond drill rigs are currently at Cariboo. Mosquito Creek and Shaft Zone deposits are located on Island Mountain. To date in 2021, a total of 133 drill holes have been drilled on Island Mountain, designed to infill and expand known vein corridors. Recent results include holes IM-21-001 to IM-21-010. A total of 124 mineralized vein corridor solids are modelled on Island Mountain, to an average depth of 350 meters, to a maximum depth of 700 meters and remain open. Recent drill results show significant down dip expansion of modelled vein corridors illustrated in IM-21-009 that intersected 23.32 g/t Au over 15.0 meters. Recent Drilling Highlights: 21.94 g/t Au over 2.70 meters in hole IM-21-003; 23.48 g/t Au over 2.30 meters in hole IM-21-004; 5.24 g/t Au over 10.85 meters in hole IM-21-004; 13.39 g/t Au over 4.10 meters in hole IM-21-005 including 41.30 g/t Au over 1.30 meters; 23.32 g/t Au over 15.00 meters in hole IM-21-009 including 85.80 g/t Au over 1.00 meter and 118.50 g/t Au over 1.00 meter 16.83 g/t Au over 4.40 meters in hole IM-21-010 including 73.40 g/t Au over 0.80 meter. Mineralized quartz veins on Cariboo are overall sub-vertical dip and northeast strike. Vein corridors are defined as a high-density network of mineralized quartz veins within the axis of the last folding event's folds and hosted within a brittle meta-sandstone or calcareous meta-sandstone. Vein corridors are modelled at a minimum thickness of 2 meters and average about 4.5 meters true width. Individual mineralized veins within these corridors have widths varying from centimeters to several meters and strike lengths from a few meters to over 50 meters. These corridors have been defined from surface to a vertical depth averaging300 meters and remain open for expansion at depth and along strike. Gold grades are intimately associated with quartz vein-hosted pyrite as well as pyritic, intensely silicified wall rock haloes in close proximity to the veins. True widths are estimated to be 60% to 75% of reported core length intervals. Intervals not recovered by drilling were assigned zero grade. Top cuts have not been applied to high grade assays. Following the closing of the reverse takeover bid transaction by Osisko Gold Royalties on November 25, 2020 which lead to the launch of the Corporation and the transfer of certain Osisko Gold employees to the Corporation on January 1st, 2021, Osisko Gold and the Corporation mutually agreed that a pro-rata portion of the outstanding long-term equity incentive compensation awarded by Osisko Gold to transferred employees in the form of restricted shares units would be borne by the Corporation. The Boards of Directors of Osisko Gold and the Corporation, agreed that Osisko Gold would cancel a pro-rata portion of the outstanding restricted shares units awarded by Osisko Gold to transferred employees and the Corporation would grant to such transferred employees restricted shares units in an equivalent value as the value of the Osisko Gold RSU cancelled by Osisko Gold; which values were determined using a 5-day volume weighted average price of the respective entity on the exchange at a pre-determined reference date. Accordingly, the Corporation is pleased to announce that its Board of Directors has approved the grant and 404,240 Replacement RSUs were granted to officers who held Osisko Gold RSUs that were cancelled. The maturity date shall be the same as the maturity date of the corresponding Osisko Gold RSUs so cancelled.

08:35 EDT Everbridge's Digital Wayfinding solution launched in RVH in Ontario - Everbridge announced that Royal Victoria Regional Health Centre, RVH, in Ontario launched Everbridge's Digital Wayfinding navigation solution to help improve the patient and visitor experience. Digital Wayfinding features turn-by-turn indoor navigation and positioning for real-time, step-by-step directions as well as 'Where am I?' location points within the building. The RVH Maps app provides a step-by-step navigation tool that helps direct patients and visitors to any RVH location, including off-site locations. The app provides a directory of RVH departments, treatment clinics, programs and services along with detailed directions of how to get to a destination. Upon launching the RVH Maps app from home, the app will navigate users to RVH using Google Maps, then will display a 3-D map of RVH with written and voice prompt directions that follows the user, even rerouting them if they go off course. The tool is available in mobile app stores by searching and downloading 'RVH Maps' or by visiting RVH Maps on the web.

08:34 EDT Fusion Pharmaceuticals to build radiopharmaceutical manufacturing facility - Fusion Pharmaceuticals entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing Practice compliant radiopharmaceutical manufacturing facility. The facility, to be built by McMaster and equipped and validated by Fusion, will be designed to support manufacturing of the company's pipeline of targeted alpha therapies. Fusion expects the manufacturing facility will be operational by early 2024.

08:33 EDT SolGold, Cornerstone to advance Cascabel Project in Ecuador - SolGold and Cornerstone Capital Resources are pleased to announce they have agreed to work cooperatively to advance the Cascabel Project in northern Ecuador. Concurrently with advancing the Cascabel Project, the Parties will explore and evaluate a range of strategic and financing options focused on maximizing value for their respective shareholders with respect to the Cascabel Project. The respective Boards of Directors of the Parties are committed to this strategy while simultaneously supporting management and employees in their ongoing efforts to advance the Cascabel Project including finalization and delivery of a new technical report. Both SolGold and Cornerstone believe that pursuing these complementary paths is in the best interests of their respective shareholders, employees and stakeholders and is designed to maximize value for each company.

08:33 EDT Deluxe names Scott Bomar as Chief Financial Officer - Deluxe (DLX) named Scott Bomar Senior Vice President and Chief Financial Officer. Bomar officially joins the company on June 14. Bomar joins Deluxe from the Home Depot (HD), where he held senior executive finance and operating leadership roles of increasing responsibility for 15 years.

08:31 EDT Circa Resort and Casino chooses Aruba to deploy Wi-Fi points across its hotel - Aruba, a Hewlett Packard Enterprise company (HPE), announced that Circa Resort and Casino, the first new downtown Las Vegas hotel and entertainment venue in over 40 years, has selected an end-to-end Aruba ESP-based network to deliver experiences at the 35-story, 777-room sports-themed property, as well as to satellite locations throughout Nevada, Colorado, and other jurisdictions, while saving nearly half a million dollars. Working with Evotek, Circa deployed a future-ready wireless network comprised of Aruba's Wi-Fi 6 indoor access points, outdoor APs, hospitality APs, and mobility controllers. For wired networking, Circa implemented Aruba's aggregation switches at the edge and CX Series switches in the data center. Beyond enabling onsite multicasting, Circa is providing modern in-room experiences such as connected lighting and IP TVs. "Deploying Aruba's wireless to guest rooms not only addresses user expectations, it also saved us nearly $500,000 versus installing a gigabyte passive optical network," said Ballard. "Aruba's licensing model was also significantly more attractive."

08:29 EDT Vera Bradley announces limited-edition 'Love Stripe' collection - Vera Bradley announced it has designed a limited-edition "Love Stripe" collection in recognition of Pride Month to support the belief that inclusion, acceptance and love can create a brighter world for all. Featuring a rainbow palette of bright watercolor stripes, Vera Bradley's Love Stripe collection includes two of the brand's new Utility styles, both consciously crafted from recycled cotton: the Utility Sling Backpack and Utility Small Crossbody. One of the brand's best-selling Plush Throw Blankets and a PopSockets PopGrip complete the collection. Styles from Vera Bradley's Love Stripe collection range in price from $14.99 - $65 and are now available in all Vera Bradley Full Line Stores and on verabradley.com

08:28 EDT Motorcar Parts announces extension of credit facility - Motorcar Parts of America announced it has extended the maturity date of the loan agreement of the company's existing credit facility led by PNC Bank, N.A. to May 2026 - including amendments which further enhance the company's strong liquidity base. The credit facility amount remains unchanged, with an aggregate facility of approximately $269M - consisting of a $238.62M revolver and a $30M term loan facility. "The extension and related amendments recognize the company's strategic milestones and the further benefits we expect to realize from our investments. We are gratified by the ongoing support of PNC Bank and the loan syndicate, and look forward to a continued strong working relationship," said Selwyn Joffe, chairman, president and chief executive officer.

08:27 EDT Travere Therapeutics completes enrollment in Phase 3 PROTECT Study - Travere Therapeutics announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that often progresses to end-stage kidney disease. Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021. The PROTECT Study is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled pivotal Phase 3 clinical trial evaluating the safety and efficacy of sparsentan in approximately 380 patients with IgAN. The PROTECT Study protocol provides for an unblinded analysis of at least 280 patients to be performed after 36 weeks of treatment to evaluate the primary efficacy endpoint - the change in proteinuria at Week 36 from baseline. The interim assessment of the PROTECT Study is designed to support potential submissions under the Subpart H pathway for accelerated approval in the United States, and potential Conditional Marketing Authorization in Europe. Secondary efficacy endpoints include the rate of change in eGFR following the initiation of randomized treatment over 58-week and 110-week periods, as well as the rate of change in eGFR over 52-week and 104-week periods following the first six weeks of randomized treatment in approximately 380 patients.

08:26 EDT Marathon Digital produces 226.6 bitcoins in May - Marathon Digital Holdings published unaudited bitcoin production and miner installation updates for May 2021. Corporate Highlights as of June 1, 2021: Produced 226.6 new minted bitcoins during May 2021, increasing total bitcoin holdings to approximately 5,518 with a fair market value of approximately $203.4 million; Cash on hand was approximately $191.8 million and total liquidity, defined as cash and bitcoin holdings, was approximately $395.1 million; Received approximately 16,809 S-19 Pro ASIC miners from Bitmain year to date with an additional 1,911 S-19 Pro ASIC miners currently in transit; Increased active mining fleet to approximately 17,655 miners, generating approximately 1.9 EH/s' On May 31, 2021, announced that the Company's Bitcoin mining pool, MaraPool, was adopting and implementing Bitcoin Core version 0.21.1. As of June 1, 2021, Marathon's mining fleet has produced approximately 580.5 newly minted bitcoins during 2021. By month, the Company's bitcoin production was as follows: January 2021: 50.4 BTC; February 2021: 43.4 BTC; March 2021: 97.9 BTC; April 2021: 162.1 BTC; May 2021: 226.6 BTC. As a result, Marathon currently holds approximately 5,518 BTC, including the 4,812.66 BTC the Company purchased in January 2021 for an average price of $31,168 per BTC. On May 31, 2021, the fair market value of one bitcoin was approximately $36,857, implying that the approximate fair market value of Marathon's current bitcoin holdings is approximately $203.4 million. As of June 1, 2021, Bitmain has delivered approximately 16,809 S-19 Pro ASIC miners to the Company's mining facility in Hardin, MT, all of which were delivered on time and as scheduled. During the month of May, Marathon installed 5,571 new miners, increasing the Company's active mining fleet to approximately 17,655 miners, generating approximately 1.9 EH/s. New miners continue to be installed on a daily basis. Based on current delivery and installation schedules, Marathon continues to expect all previously purchased miners to be fully installed by the end of the first quarter of 2022, at which point, the Company's mining fleet will consist of approximately 103,120 miners, generating approximately 10.37 EH/s. On May 31, 2021, Marathon announced that the Company's Bitcoin mining pool, MaraPool, was adopting and implementing Bitcoin Core version 0.21.1, which includes the Taproot soft fork, without modification. As a result, MaraPool will no longer filter transactions. The update is expected to begin this week with Taproot signaling commencing the following week, at which point, the pool will begin validating transactions in a manner consistent with all other miners who use the standard node.

08:25 EDT Qad Inc. signs partnership agreement with TCC Technology in Thailand - QAD announced that it has signed a partnership agreement with Bangkok-based T.C.C. Technology, making TCCtech a channel partner in Thailand. "TCCtech is Thailand's leading carrier-neutral data center. Carrier-neutral data centers allow interconnection between colocation and interconnection providers. The company provides best-in-class infrastructure services, managed services and business solutions," the company said. Under the terms of the agreement, TCCtech will provide consultation to prospective customers during the pre-sales process for QAD Adaptive ERP.

08:24 EDT Rain Therapeutics enters patient referral partnership with Caris - Rain Therapeuticsy announced a patient referral partnership with Caris Life Sciences. Under the terms of the partnership, Caris will provide patient referral services using their molecular intelligence trials platform for Rain's planned Phase 2 MDM2-amplified tumor-agnostic basket trial for RAIN-32, an oral MDM2 inhibitor in patients with certain solid tumors with pre-specified MDM2 amplification levels and wild type p53.

08:23 EDT Just Energy to commence trading on the TSX Venture Exchange - Just Energy Group announced that the common shares of the Company will commence trading on the TSX Venture Exchange at 9:30 a.m. Eastern Daylight Time on Friday, June 4, 2021 under the ticker symbol "JE". The common shares of Just Energy will be delisted from the Toronto Stock Exchange at 5:01 p.m. Eastern Daylight Time on Thursday, June 3, 2021, and will be listed on the TSX Venture Exchange at the same time.

08:22 EDT Midland States completes acquisition of ATG Trust Company - Midland States Bancorp has completed its acquisition of substantially all of the trust assets of ATG Trust Company. The transaction increases the size of Midland's wealth management business to approximately $4.1 billion in assets under administration and 90 financial professionals with a new, larger office in Chicago.

08:21 EDT Genmab, Bolt announce oncology research, development agreement - Genmab (GMAB) and Bolt Biotherapeutics, Inc. (BOLT) announced that the companies have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt's proprietary Boltbody immune-stimulating antibody conjugate technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer. This research collaboration will evaluate multiple bispecific ISAC concepts to identify up to three clinical candidates for development. Genmab will fund the research, along with the preclinical and clinical development of these candidates through clinical proof of concept. Under the terms of the agreement, Genmab will pay Bolt an upfront payment of $10 million. Genmab will also make a $15 million equity investment in Bolt. Bolt is eligible to receive total potential milestone payments of up to $285 million per therapeutic candidate exclusively developed and commercialized by Genmab, along with tiered royalties. Genmab will fully fund pre-clinical and early clinical development of all candidates. If a candidate is co-developed, development costs will be split 50:50 between the two companies, and the companies will be solely responsible for commercialization costs in their respective territories and shall pay each other royalties on product sales.

08:20 EDT Celsion urges shareholders to vote at 2021 Annual Meeting - Celsion Corporation reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, June 4, 2021 at 10:00 a.m., Eastern Time and called on stockholders to vote to ensure that a quorum is present to hold the meeting. Stockholders holding common stock at the close of business on April 5, 2021 are entitled to vote at the meeting. Meeting materials, including the definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2021, along with a proxy card, were mailed on April 21, 2021, to stockholders of record as of April 5, 2021 and made available at www.sec.gov. Celsion is also asking stockholders to follow the Board of Directors' recommendation to vote FOR Proposal #3 to increase the number of authorized shares of common stock. Proposal #3 involves an amendment to the Company's Certificate of Incorporation and therefore requires a majority of all shares outstanding to vote FOR this proposal in order for it to pass. ISS and Glass Lewis have both recommended that stockholders vote FOR the Company's proposal to increase the number of authorized shares. There are four proposals to be voted on during the June 4th meeting. Please review the information regarding each of these proposals in their entirety, which can be found in the definitive proxy statement filed with the SEC on April 20, 2021. As stated in the Proxy, Proposal #3 is being presented to increase the number of shares of the Company's common stock authorized for issuance from 112,500,000 to 172,500,000. The Board of Directors believes that the increase in authorized common shares will provide the Company with the ability to support its future anticipated growth and would provide the Company with greater flexibility to consider and respond to future business opportunities and needs as they arise, including stock-based acquisitions of new technology and product development candidates and equity financings. The availability of additional shares of Common Stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of our Common Stock

08:18 EDT MDC Partners special committee issues response to Indaba Capital - MDC Partners' Special Committee of Independent Directors released a letter in response to Indaba Capital Management's letter sent on May 26 regarding the proposed business combination involving MDC Partners and Stagwell Media. The letter states, among other things: "(...) we are surprised that you continue to misunderstand our process, the negotiation history, the strategic rationale for the transaction and the significant value the transaction has, and we believe, will continue to create for MDC shareholders. (...) after many hard negotiations which achieved substantial increases in value for MDC shareholders, we were told by Stagwell that it was unwilling to provide MDC shareholders with more. (...) In the meantime, MDC stock has rallied from $1.15 per share - before Stagwell publicly indicated its interest in combining with MDC in June 2020 - to nearly $5 per share now. This price movement is the hallmark of a transaction that has been well received by shareholders broadly. (...) Once you privately and publicly indicated your intention to vote against the deal, the stock declined as shareholders began to fear that this accretive transaction may not be approved. (...) we believe your concerns about the transaction are unfounded and misguided. (...) You are correct, of course, that Mr. Penn is both the Chairman and CEO of MDC and the Managing Partner of Stagwell. As a result, within hours of Mr. Penn proposing a business combination transaction involving MDC and Stagwell, the MDC Board empaneled a Special Committee of independent directors to ensure the interests of MDC's public shareholders were protected. (...) Mr. Penn was always seen by the Special Committee as our counterparty, and we negotiated against him vigorously. (...) The transaction was negotiated between the Special Committee and Stagwell over a six-month period. During that time, the Special Committee conducted extensive diligence on the Stagwell business and sought, and received, significant improvements in the economics and transaction terms. (...) two independent financial advisors to the Special Committee rendered opinions that the percentage ownership of New MDC to be held by the holders of the MDC common shares upon completion of the Transaction is fair, from a financial point of view, to such holders (...) There are benefits to MDC from cross-selling, cost savings and market positioning opportunities that can uniquely be achieved through a combination with Stagwell. (...) The new MDC will have manageable leverage, new digital capabilities and the ability to truly compete against the big four ad holding companies for the most lucrative marketing assignments from global clients. (...) We believe MDC's stock price would not be at these levels in the absence of the Stagwell deal because the market recognizes the unique merits of this combination. (...) We firmly believe that voting against this transaction is a mistake and risks leaving MDC in a much weaker position, with too much leverage and too little scale, and without the critical digital capabilities to compete in the future. (...) We encourage Indaba to reconsider its stated opposition and join with other MDC shareholders to vote for this combination".

08:16 EDT Ibex, Wixcrop enter strategic partnership for healthcare patient experiences - ibex and Wixcorp announced a strategic partnership that will enhance the patient financial experience across the healthcare vertical. The movement toward patients as healthcare consumers, COVID-19-driven digital transformation, and sharp financial declines have accelerated the need for digital experiences that combine outsourced billing support with self-pay options that make the patient experience simple and easy. Unfortunately, hospitals and providers are behind the curve when it comes to evolving their business models. To address this need, ibex and Wixcorp are launching a joint solution that combines industry-leading customer support with a transformative suite of innovative, cloud-based patient financial solutions to increase patient satisfaction by converting traditional financial complexities into a simple, intuitive and engaging experience. The ibex Wixcorp solution optimizes the patient journey, providing a consumer-facing revenue management solution that supports and empowers their customers' patients. This includes technology-driven cost estimation, scheduling, and self-pay payment options all embedded in Wixcorp's Redde technology platform. Customers also benefit from experienced business process outsourcing provided by ibex, leveraging its world-class contact center operations and customer support agents to provide exceptional billing customer service.

08:15 EDT Boehringer Ingelheim, Zealand Pharma granted FTD from FDA for NASH treatment - Boehringer Ingelheim and Zealand Pharma A/S announced that the US Food and Drug Administration has granted Fast Track Designation, or FTD, to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis, or NASH. The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis with and without diabetes. The GLP-1/glucagon compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments. It is also being investigated as a potential treatment option for adults living with diabetes and for adults living with obesity. It is part of Boehringer Ingelheim's research and development portfolio in the cardiometabolic disease areas.

08:13 EDT CarMax to hire1,800 automotive service professionals nationwide - CarMax announces plans to hire 1,800 automotive service professionals by the end of summer - kicking off with the first-ever CarMax Curbside Career Day on June 10 from 10 a.m. - 3 p.m. CarMax is partnering with job site Indeed to hold curbside hiring events at 16 CarMax locations across the country. The company will be interviewing candidates for a variety of positions for automotive service professionals, including technicians, detailers, painters, supply associates, and more. There will be job opportunities for both new and seasoned automotive professionals, with potential for jobs to be offered on the spot. Some positions will also offer sign-on bonuses. CarMax is the largest buyer and seller of used autos from and to customers in the United States. Newly hired automotive service professionals will help the company increase its production of vehicles for retail to support the company's increasing demand. CarMax's highly trained associates will primarily work on reconditioning vehicles and preparing them for sale. "CarMax continues to grow and the need to produce more vehicles to keep up with anticipated consumer demand is great," said vice president of regional service operations, Tyrone Payton. "We are introducing CarMax Curbside Career Day as an opportunity for automotive professionals across the country to check out our award-winning culture in-person and learn why CarMax is the best place to work."

08:12 EDT Cypress Development appoints Cassandra Joseph to board of directors - Cypress Development announced that Cassandra Joseph, Esq., has been appointed to the Company's Board of Directors. Joseph is an attorney with more than 20 years of experience working in the U.S. in natural resource, environmental and corporate law. She is presently Senior Vice President, General Counsel and Corporate Secretary for Nevada Copper Corp.

08:10 EDT Galecto to host KOL webinar on myelofibrosis treatment landscape - Galecto announced that it will host a key opinion leader webinar on the myelofibrosis treatment landscape and the current and potential future treatments on Wednesday, June 9, 2021 at 8am Eastern Time. The webinar will feature a presentation by KOL Srdan Verstovsek, MD, Ph.D., UT MD Anderson Cancer Center, who will discuss the current treatment landscape and unmet medical need in treating patients with myelofibrosis, a fibrosis-related blood cancer. He will also discuss the opportunity for Galecto's GB2064 as a potential treatment option and Hans Schambye, Galecto's President and CEO, will update its development status. Dr. Verstovsek will be available to answer questions following the formal presentations with Galecto's management team. GB2064 is an oral LOXL2 inhibitor that the company plans to examine in a Phase 2a study for the treatment of myelofibrosis. LOXL-2 is upregulated in myelofibrosis fibrotic tissue and plays a key role in fibrosis and disease progression in the tumor micro-environment; and as such, inhibiting LOXL-2 may restore bone marrow function and be disease-modifying. The current standard of care for myelofibrosis is JAK inhibitors, but their use is limited by side effects and loss of efficacy in many patients.

08:09 EDT Skillz jumps over 8% to $18.36 after announcing $150M Aarki acquisition

08:09 EDT Arrow Electronics announces Fabian Garcia as new director to board - Arrow Electronics (ARW) announced that Fabian Garcia, president, Unilever (UL) North America, and a member of the Unilever Leadership Executive Team, has joined the company's board of directors. The addition of Garcia and the retirement of M.F. Keeth leaves the total number of directors on the board at 11.

08:06 EDT Apollo Medical to acquire controlling interest in Sun Labs for $4M - Apollo Medical announced that the company has entered into a definitive agreement with Sun Clinical Laboratories, under which ApolloMed will purchase controlling interests in Sun Labs for $4M. Sun Labs is a CLIA-certified full-service lab that operates 19 locations across the San Gabriel Valley in southern California. The combination will allow ApolloMed to fully incorporate Sun Labs, an existing partner, into its integrated value-based care delivery platform, leading to greater operational efficiencies for ApolloMed and more integrated care for ApolloMed's members. ApolloMed will have the opportunity to leverage its extensive network and business development expertise to guide the expansion of Sun Labs into other geographic regions. Upon closing, ApolloMed expects to consolidate Sun Labs' financials into its GAAP results.

08:05 EDT Horizon Therapeutics presents new data from PROTECT study on KRYSTEXXA - Horizon Therapeutics presented new data during the EULAR European Congress of Rheumatology from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA as a treatment for people with uncontrolled gout who have undergone a kidney transplant. The Prospective Study of Pegloticase in Transplant patients trial is an ongoing Phase 4, multi-site, open-label trial evaluating the safety and efficacy of KRYSTEXXA in adults with uncontrolled gout who have received a kidney transplant and are on stable immunosuppressive therapy. Participants are receiving KRYSTEXXA to determine response rate during Month 6. At time of data cut, estimated glomerular filtration rate, a key indicator of kidney function, remained stable for all patients throughout KRYSTEXXA treatment. In the 10 patients with Week 24 eGFR measurements, the mean eGFR was 41.6 +/- 10.6 mL/min/1.73 m2 at baseline and 43.8 +/- 11.9 mL/min/1.73 m2 at Week 24, with a mean improvement of 2.3 +/- 8.1 mL/min/1.73 m2 during the treatment. Further, through health assessment questionnaires, patients reported clinically meaningful reductions in pain and disability. The PROTECT trial was fully enrolled in January 2021 with 20 patients who received a kidney transplant and as such were on two to three immunosuppressive agents each. At the time of data analysis, 10 patients had completed the full course of therapy and five were receiving ongoing treatment; three patients discontinued the study and two discontinued treatment due to meeting sUA monitoring protocols. In the trial, 15 patients experienced an adverse event, with the majority reporting mild-to-moderate events, none of which led to discontinuation of therapy. No anaphylaxis or infusion reaction events were reported. The trial is expected to be completed in Fall 2021. Preliminary findings of the PROTECT clinical trial: pegloticase efficacy and safety in kidney transplant recipients.

08:04 EDT Tabula Rasa HealthCare extends contract with ArchCare - Tabula Rasa HealthCare announced a five year contract renewal with ArchCare Senior Life, a Program of All-Inclusive Care for the Elderly serving more than 700 participants from multiple centers throughout the New York metro region. ArchCare will continue to rely on TRHC's pharmacy and medication management services, including its medication decision-support technology, MedWise, to identify simultaneous, accumulative, multi-drug interactions. Using MedWise, embedded in TRHC's PACE-specific software, ArchCare providers are able to make informed decisions at the point of prescribing to improve medication safety, efficacy, and adherence. By extending this long-standing relationship, ArchCare will continue to have access to certified MedWise Advisor pharmacists who provide recommendations for interventions that reduce risks and improve medication outcomes.

08:00 EDT Scynexis trading resumes

07:50 EDT Constellation Pharmaceuticals trading resumes

07:44 EDT Royalty Pharma, MorphoSys announce $2.025B strategic funding partnership - Royalty Pharma (RPRX) and MorphoSys AG (MOR) announced a $2.025B strategic funding partnership as part of MorphoSys' $1.7B acquisition of Constellation Pharmaceuticals (CNST). This partnership is expected to fuel the expansion of the combined company's capabilities to help enable the development and potential approvals of important cancer treatments. This funding partnership is anchored by Royalty Pharma's acquisition of MorphoSys' rights to receive future royalties on Janssen's Tremfya. Tremfya is an anti interleukin (IL)-23, approved for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis and is also in clinical development for ulcerative colitis and Crohn's disease. In 2020, Tremfya generated sales of $1.347B Royalty Pharma will also acquire the rights to receive royalties and certain milestone payments on four attractive development-stage therapies: Gantenerumab, an anti-amyloid-beta monoclonal antibody, in Phase 3 development for Alzheimer's disease by Roche. Royalty Pharma will purchase the rights to receive 60% of MorphoSys' future royalties on gantenerumab. Otilimab, a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor, in Phase 3 development for rheumatoid arthritis by GlaxoSmithKline. Royalty Pharma will purchase the rights to receive 80% of MorphoSys' future royalties and 100% of its future milestones on otilimab. Pelabresib, a bromodomain and extra-terminal nhibitor for myelofibrosis, in Phase 3 development by Constellation. Royalty Pharma will purchase the rights to receive 3% of future net sales of pelabresib. CPI-0209, a second-generation enhancer of zeste homolog 2 inhibitor, in Phase 2 development for hematological malignancies and solid tumors by Constellation. Royalty Pharma will purchase the rights to receive 3% of future net sales of CPI-0209. The long-term strategic funding partnership agreement is comprised of the following terms: $1.425B upfront payment: In exchange for the rights to receive 100% of MorphoSys' future royalties on Tremfya, 80% of MorphoSys' future royalties and 100% of MorphoSys' future milestone payments on otilimab, 60% of MorphoSys' future royalties on gantenerumab, and 3% of future net sales of Constellation's clinical stage assets, Royalty Pharma will make a $1.425B upfront payment to MorphoSys, supporting its growth strategy. The proceeds will be used to support the financing of the Constellation transaction and the development of the combined pipeline. Milestone payments: Royalty Pharma will make additional payments to MorphoSys of up to $150M upon reaching certain milestones for otilimab, gantenerumab and pelabresib. $350M Development Funding Bonds: Royalty Pharma will provide MorphoSys with access to up to $350M in Development Funding Bonds, with the flexibility to draw over a one year period, with a minimum draw of $150M. Equity Investment: After completion of the transaction, Royalty Pharma will purchase $100M of ordinary shares of MorphoSys based on the average trading price of the shares over a period preceding the closing of the transaction. The investment will be subject to the required resolutions by the management board and the supervisory boar of MorphoSys, and will constitute a cash capital increase of MorphoSys under an authorization to exclude subscription rights of existing shareholders. The new shares will be listed on the Frankfurt Stock Exchange.

07:41 EDT ONCAP purchases majority stake in Komar Industries, terms not disclosed - ONCAP announced it has purchased a majority stake in Komar Industries, in partnership with the Koenig family. Headquartered in Groveport, OH, Komar is a designer and manufacturer of industrial waste and recycling processing systems. The Company specializes in auger processing technology and provides a comprehensive portfolio of products, including auger compactors, industrial shredders, continuous feed systems, flatteners / dewatering systems, and organic separation presses. Established in 1977, and still managed by the founding Koenig family, Komar's products enable its customers to improve their processing of waste streams while reducing their carbon footprint and their transportation, energy, maintenance, and labor costs. The investment was made by ONCAP IV, Onex Corporation's $1.1B fund. The terms of the transaction are not being disclosed.

07:39 EDT Southwestern Energy to acquire Indigo Natural Resources for total of $2.7B - Southwestern Energy announced that it has entered into a definitive merger agreement with Haynesville producer Indigo Natural Resources under which it will acquire Indigo for approximately $2.7B. The transaction is expected to close early in the fourth quarter of 2021, subject to customary closing conditions. "Today we are proud to announce another accretive transaction that will benefit the Company's shareholders for years to come. This acquisition enhances Southwestern's position as a leading natural gas producer and aligns with our disciplined strategy to generate free cash flow, enhance our balance sheet, optimize performance and build scale. Indigo has done a terrific job building its business, and its balance sheet strength, low cost structure and high-quality acreage position in the core of the Haynesville play accelerates the delivery of our strategic goals," said Bill Way, Southwestern Energy President and Chief Executive Officer. The total consideration of $2.7B will be comprised of $400M in cash, approximately $1.6B in SWN common stock and $700M of assumed 5.375% senior notes due 2029. The stock consideration consists of approximately 339M shares of Southwestern Energy common stock, calculated utilizing the 30-day volume-weighted average price as of May 28, 2021, of $4.72. No Indigo shareholder will receive more than 10% of Southwestern Energy's pro forma outstanding shares in connection with this transaction. The transaction was unanimously approved by each of Southwestern Energy's and Indigo's board of directors. The transaction is expected to close early in the fourth quarter of 2021, subject to regulatory approvals, customary closing conditions and the approval by Southwestern Energy's shareholders.

07:38 EDT Hyzon Motors announces order for up to 70 hydrogen trucks - Hyzon Motors announced it has entered into a definitive agreement with JuVe Automotion GmbH for the sale of hydrogen fuel cell powered heavy duty trucks. JuVe is a spin-off of the Austrian grocer MPREIS's hydrogen initiative, and will be supplying the trucks to MPREIS and other first movers in the hydrogen fuel cell space. This comes ahead of Hyzon's public listing via a definitive business combination agreement with Decarbonization Plus Acquisition Corporation. The initial delivery is planned for Q4 of 2021, with the remaining trucks to be delivered over the course of three years. The first batch of vehicles includes three different heavy-duty trucks, including tractor/puller and rigid chassis designs, and are built to support refrigeration units. The Hyzon trucks are expected to be assembled at Hyzon's European facility in the Groningen area of the Netherlands, where orders have already been confirmed for deliveries of Hyzon-branded commercial vehicles to several countries around the world.

07:37 EDT Helius Medical appoints Frederick Fantazzia as VP, sales & marketing, N. America - Helius Medical Technologies (HSDT) announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021. Prior to joining Helius, Mr. Fantazzia worked for LivaNova (LIVN). He most recently served as Vice President of North America Sales and Marketing for LivaNova's Epilepsy business, where he managed all aspects related to its commercialization of a neuromodulation technology for the treatment of drug-resistant epilepsy.

07:36 EDT Skillz to acquire Aarki for $150M in cash, stock transaction - Skillz announced it has entered into an agreement to acquire Aarki, a technology-driven marketing platform. "The acquisition will broaden Skillz's footprint across the rapidly expanding mobile gaming industry by combining its competitive platform with Aarki's advanced advertising capabilities," the company said. "Aarki's proven machine learning will pair with Skillz's robust first-party data to create an unrivaled value proposition for game developers," said Skillz CEO Andrew Paradise. "The integrated ecosystem will unlock new points of connectivity between consumers, developers, and brands, pairing the right impression with the right user at the right time, all while delivering a superior user experience." Aarki is headquartered in Sunnyvale, CA and its approximately 160 employees will join the Skillz workforce, with Budagyan continuing to lead the business as a division of Skillz. Skillz will acquire 100% of Aarki for approximately $150M in cash and stock. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2021.

07:35 EDT CME Group reached ADV of 20.6M contracts in May - CME Group reported May market statistics, including average daily volume of 20.6M contracts during the month.

07:34 EDT Home Depot recommends shareholders reject "mini-tender" offer by Tutanota - Home Depot has been notified that Tutanota has made an unsolicited "mini-tender" offer to purchase up to 1 million shares of Home Depot's common stock, at an offer price of $360 per share. While this offer price is above the current market price of the company's common stock, the offer is conditioned upon, among other things, the closing price of Home Depot's common stock exceeding $360 per share on the last trading day before the offer expires. This means that shares tendered in the offer will only be accepted if the offer price is below the closing market price. In fact, the offer states that as of the date of the offer, Tutanota expects to extend the offer until the market price of Home Depot's common stock exceeds the offer price. The Home Depot recommends that shareholders do not tender their shares in response to Tutanota's offer because the offer requires that the closing stock price for the company's common stock exceed the offer price, and it is subject to numerous additional conditions, including Tutanota obtaining financing for the offer, which Tutanota states it does not currently have. The Home Depot does not endorse Tutanota's unsolicited mini-tender offer and is not affiliated or associated in any way with Tutanota, its mini-tender offer, or its mini-tender offer documents. Tutanota's purported mini-tender offer seeks less than 5% of Home Depot's outstanding common stock, thereby avoiding many disclosure and procedural requirements of the SEC that apply to offers for more than 5% of a company's outstanding shares. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under U.S. securities laws.

07:34 EDT Visa says May operational metrics 'generally consistent or better than April' - In a regulatory filing last night, Visa stated: "Visa continues to monitor the COVID-19 impact globally. As we began to lap the most significant COVID-19 impacts starting in March 2020, year-over-year growth rates were not reflective of the underlying trend, therefore performance metrics relative to fiscal 2019 have also been provided. Compared to fiscal 2019 levels, operational metrics in May were generally consistent or better than April levels. For U.S. payments volume in May, Credit continued to improve, up 3 points from April as compared to 2019 levels, while Debit remained elevated at 151% of 2019. Card not present excluding travel remained strong at 159% of 2019 and card present increased 4 points from April to 113% of 2019. Excluding travel, May spend was at least 10 points above 2019 levels in each industry category. While travel spend was still below 2019 levels, it has steadily improved over the last several months relative to 2019, expanding about 30 points from January through May. International market payments volume trends in May versus the same period in 2019 were relatively stable to April trends, with the exception of India, which continued to slow, and several other Asian countries that were impacted by new COVID-related restrictions. Conversely in Europe, many countries improved versus 2019 levels with the relaxing of COVID-related restrictions. Cross-border volume excluding intra-Europe transactions improved 6 points to 85% of 2019 in May, with card not present excluding travel volume remaining elevated at 162% of 2019 and travel-related spend - card present and card not present - improving 5 points from April to 45% of 2019. Total cross-border volume increased to 98% of 2019 in May. Global processed transactions were 121% of 2019 in May, which was higher than in previous months as transactions increased along with volume in several countries, particularly in Europe."

07:33 EDT BriaCell reports 12 Months OS benefit in advanced breast cancer - BriaCell Therapeutics provides an update on the overall survival data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell's lead candidate Bria-IMT as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab KEYTRUDA ; manufactured by Merck & Co and Incyte's retifanlimab HLA-Typing: Cells with HLA molecules on their surface determine and trigger the body's immune response. BriaCell's immunotherapy treatment appears most effective when the patient's HLA-type matches with Bria-IMT, allowing BriaCell to potentially identify patients most likely to respond. HLA-typing is a simple and widely available test. Tumor Grade: BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for whom BriaCell's treatment would be most effective.

07:32 EDT Jones Lang LaSalle appoints Kylie Kendrick as COO - Jones Lang LaSalle appointed Kylie Kendrick to the newly established role of COO effective June 7. Kendrick joins JLL from HSBC in London where she was Managing Director - Global Head of Wholesale Banking Operations. Her experience of over 16 years at financial institutions includes Lloyds Banking Group, Deutsche Bank, Barclays and Deloitte Consulting.

07:31 EDT Toyota debuts all-electric SUV concept in U.S. - The Toyota bZ4X Concept touched down to make its North American debut at Toyota Motor North America's headquarters. Already a leader in electrification, the company has taken a major step forward with the introduction of the Toyota bZ4X Concept, the vision for the first of a global series of battery-electric vehicles to be introduced under the "Toyota bZ" brand umbrella. Jointly developed with Subaru, the Toyota bZ4X SUV Concept features the new e-TNGA BEV-dedicated platform. The concept conveys Toyota's legendary quality, durability and long-term reliability in combination with AWD capabilities to achieve a driving experience that is both comfortable and engaging. Toyota envisions a future in which carbon neutrality is achieved through the practical marketization of a portfolio of products with advanced, alternative-fuel and zero-emission powertrain technologies. Overall, Toyota plans to expand to around 70 electrified models globally by 2025. This future lineup will feature 15 dedicated BEVs, including seven carrying the bZ (Beyond Zero) brand moniker. In addition, Toyota intends to bring electrification to its pickup truck lineup in the near future. This diverse portfolio of electrified products will help propel Toyota toward its goal of carbon neutrality by 2050.

07:29 EDT Skylight Health announces award of US clinical trial - Skylight Health Group announced that they have signed a contract with Adagio Therapeutics to enroll patients into the Phase 2/3 trial evaluating Adagio's monoclonal antibody, ADG20, designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19. Skylight Health's clinic in Burlington, MA will enroll both existing Skylight Health patients as well as individuals from the general population. The trial itself is a randomized, double-blind, placebo-controlled trial, meaning that participants will have a 50/50 chance of receiving either the monoclonal antibody, ADG20, or a placebo. Seeking to determine if ADG20, compared to a placebo, is safe and efficacious in preventing symptomatic COVID-19, the trial seeks to enroll two separate populations: 1 individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection; and 2 individuals who are at increased risk for SARS-CoV-2 infection. The trial population also includes individuals at risk of generating poor vaccine response, such as those who are immunocompromised. The primary endpoint is the proportion of participants with laboratory-confirmed symptomatic COVID-19 through Day 28 for the post-exposure cohort and through six months for the pre-exposure cohort. Participants will be followed for 12 months following receipt of the trial product. Approximately 100 clinics sites will participate internationally to enroll 6,400 participants for the EVADE trial.

07:27 EDT AbbVie's Rinvoq for rheumatoid arthritis shows efficacy in Phase 3 trial - AbbVie announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe rheumatoid arthritis on background methotrexate treated with Rinvoq maintained higher rates of clinical remission and low disease activity through three years compared to those patients treated with Humira. Additionally, a separate integrated safety analysis found the safety profile of Rinvoq was consistent over 4.5 years, with no new safety risks observed. In this study, a higher proportion of patients treated with Rinvoq 15 mg achieved and maintained clinical remission and low disease activity compared to those treated with Humira, through three years. A higher proportion of patients treated with Rinvoq 15 mg completed three years of treatment without rescue compared to those treated with Humira: 46% vs. 34%, respectively. In this study, through three years, the safety profile of Rinvoq 15 mg was consistent with the profile reported previously and with that shown in the Phase 3 integrated safety analysis. Additionally, the rates of events of special interest were generally comparable between the Rinvoq and Humira groups. Serious adverse events occurred at 10.9 events per 100 patient years for Rinvoq vs. 14.1 events/100PY for Humira. The rate of malignancy was 0.6/100PY on Rinvoq and 0.7/100PY on Humira. An integrated safety analysis including safety data across Rinvoq rheumatoid arthritis studies showed that the safety profile of Rinvoq 15 mg was consistent with previous analyses, with no new safety risks identified up to 4.5 years of treatment. The rate of deaths in Rinvoq-treated patients with rheumatoid arthritis remains consistent with the background rate for patients with rheumatoid arthritis.

07:25 EDT Nurix Therapeutics presents preclinical data from its NX-5948 program - Nurix Therapeutics announced the presentation of preclinical data from its NX-5948 program, demonstrating that daily oral dosing of NX-5948 resulted in a robust resolution of symptoms and inflammation in an animal model of arthritis. The data, which support further investigation of NX-5948 for clinical development as a potential treatment for autoimmune disorders, were presented at the EULAR 2021 Virtual Congress which is being held June 2-5, 2021.

07:24 EDT Progenity to discontinue genetic laboratory-developed test services through lab - Cost Realignment. Progenity will discontinue providing genetic laboratory-developed test services through its Ann Arbor, Michigan CLIA-certified laboratory and cease offering its Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. This strategic transformation is expected to be completed over the next approximately 60 days and will include a reduction in force of approximately 374 employees across Progenity and Avero, or approximately 56% of its total workforce. The transformation is also expected to result in annualized cost savings of approximately $130 million in SG&A. The company's capital requirements after accounting for the costs of the transformation are expected to be approximately $4-5 million per month before any non-dilutive inflows. Opportunities for Non-Dilutive Capital Infusion. Progenity's in-network affiliate lab, Avero Diagnostics, is approaching operating profitability, with growing revenues projected to be $35-40 million for 2021 derived from anatomic pathology, genetic testing and infectious diseases. Progenity is evaluating strategic opportunities for Avero to generate non-dilutive capital that may help fund the company. Focus on Innovation. Progenity's continuous pursuit of innovative solutions seeks to provide near-term commercial applications while also developing the drug delivery systems of the future, with critical near-term milestones across its Preecludia pre-eclampsia rule-out test, Drug Delivery System (DDS) platform, and Oral Biopharmaceutical Delivery System.

07:23 EDT Progenity launches strategic transformation into biotech company - Progenity announced a transformation strategy that will focus the company primarily on its robust R&D pipeline and better position the business for future growth. To achieve this vision, simplify its business model, and unlock shareholder value, the company will seek to reallocate resources to R&D and materially reduce operating expenditures by approximately 70%.

07:23 EDT Energizer announces price increases across global battery business - Energizer Holdings announced plans to execute broad-based price increases across its global battery business, including its alkaline, lithium, carbon zinc and rechargeable products. The company has notified customers in the U.S. and Canada of the increases, which are necessary to offset significant cost inflation, such as commodities, freight and labor. The company will implement these actions through list price changes, which will be phased in throughout fiscal 2022. The vompany expects to realize the full benefit of these changes in the back half of fiscal 2022, with increasing benefit between the first and second quarters. Combined with the recently announced price increases in auto care, the vompany has now announced price increases in over 85% of its North American business. Similar price increases are expected to be announced in its international business over the balance of the year. The company believes that these price increases, combined with its ongoing continuous improvement efforts, will be sufficient to offset the cost inflation it expects to experience in fiscal 2022. Based on the anticipated timing of implementation, battery pricing actions will not have an impact on the company's full year fiscal 2021 outlook that was disclosed with its second quarter financial results.

07:19 EDT Virios Therapeutics presents phase 2a fibromyalgia trial data on IMC-1 - Virios Therapeutics announced that clinical data from its Phase 2a trial of IMC-1 in fibromyalgia is featured in a poster presentation at the annual EULAR European Congress of Rheumatology which is being held virtually June 2 - 5. The company's poster has been selected to be highlighted in a guided tour entitled "Epidemiology and treatment of pain in Rheumatic and Musculoskeletal Disorders." IMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress Herpes Simplex Virus-1 activation and replication, with the end goal of reducing viral mediated disease burden. The conclusions made on the poster: In this post hoc analysis of a Phase 2a trial of IMC-1 in patients with FM, patients treated with IMC-1 reported significantly greater improvement compared with placebo on FIQ-R total scores and on all FIQ-R domains. Patients receiving IMC-1 treatment reported significantly greater improvements versus placebo on the FIQ-R symptom items for stiffness, sleep quality, depression, and anxiety. Improvements in patient global assessments and in fatigue assessments provide additional evidence for the beneficial effects of IMC-1 on FM related symptoms. These results suggest that IMC-1 may represent a promising treatment option not only for alleviating pain, but also for improving other symptoms associated with FM.

07:18 EDT Recro expands capacity for growing clinical trial services offerings - Recro Pharma dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it has expanded the clinical capabilities of the company's growing Clinical Trial Services offerings. Included among the newly added CTS capabilities are clinical-scale sachet and blister packaging for clinical trial pharmaceuticals.

07:16 EDT Points International powers Mashreq and Emirates Skywards rewards program - Global leader in powering loyalty commerce, Points, announced that they have launched a new service with leading UAE financial institution, Mashreq, and Emirates Skywards, the award-winning loyalty programme of Emirates and flydubai, that enables Mashreq customers to exchange their Salaam points into Skywards Miles. Mashreq customers earn reward points on transactions using eligible Mashreq debit or credit cards or via other banking solutions. Now, they can easily convert these into Skywards Miles, opening up a wealth of new reward options from flight bookings with Emirates and their partner airlines, travel packages with Emirates Holidays or even dining offers, tours and attractions and more.

07:13 EDT BlackBerry up nearly 15% in pre-market amid increased post volume on WSB board - Shares of BlackBerry are up nearly 15% in early pre-market trade above $13 per share. The stock has become the 2nd most mentioned ticker on Reddit's WallStreetBets Reddit board - behind AMC Entertainment (AMC) - with 487 mentions, TheStreet's Dan Weil reports, with about 10% of posts voicing hopes for a short squeeze even though its short interest is at 9% of the total vs. 21% for AMC and GameStop (GME). Reference Link

07:12 EDT LogicBio Therapeutics begins dosing in Phase 1/2 methylmalonic acidemia trial - LogicBio Therapeutics has dosed the first patient with LB-001, the company's investigational single-administration gene editing therapy based on its proprietary GeneRide platform, in the Sunrise Phase 1/2 clinical trial in pediatric patients with methylmalonic acidemia, or MMA. MMA is a rare and life-threatening genetic disorder for which there are currently no treatments addressing the underlying cause of the disease. To manage the symptoms and detrimental effects of MMA, patients must maintain a severely restrictive diet. The SUNRISE trial is initially enrolling patients 3-12 years old and will potentially enroll infants as young as 6 months once the first two patients meet certain safety parameters and a biomarker indicating genome integration and protein expression is detected.

07:10 EDT Renovacor appoints Marc Semigran as CMO - Renovacor announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor. Semigran brings considerable clinical development and translational medicine experience to Renovacor, having previously served as chief medical officer and senior vice president of medical science at MyoKardia. Renovacor previously announced that it had entered into a definitive business combination agreement with Chardan Healthcare Acquisition 2, a special purposes acquisition company. Completion of the proposed business combination is subject to approval by the shareholders of CHAQ and certain other conditions. The proposed business combination is expected to close in the third quarter of 2021.

07:08 EDT Lyra Therapeutics, LianBio announce partnership, license agreement for LYR-210 - Lyra Therapeutics and LianBio announced a strategic partnership and exclusive license agreement for the development and commercialization of LYR-210 in Greater China, South Korea, Singapore and Thailand. LYR-210 is an anti-inflammatory, intra-nasal drug matrix in late-stage development that is designed to treat chronic rhinosinusitis, a debilitating inflammatory disease of the nasal passages. Under the terms of the agreement, Lyra will receive an upfront payment of $12M and is eligible to receive up to $135M in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, Lyra also will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and Lyra will retain all rights to LYR-210 in all other geographies. As part of the agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to Lyra's LYR-220, an anti-inflammatory, intra-nasal, drug matrix in development for the treatment of CRS patients who have undergone a prior sinus surgery but continue to have persistent disease.

07:08 EDT Kedrion and Kamada announce FDA approval of KEDRAB label update - Kedrion Biopharma and Kamada announced the U.S. Food and Drug Administration FDA has approved a label update for KEDRAB establishing the product's safety and effectiveness in children. KEDRAB, a human rabies immune globulin is now indicated for passive, transient post-exposure prophylaxis of rabies infection in persons of all ages when given promptly following contact with a rabid or possibly rabid animal. The new updates to the KEDRAB label are based on data from the KEDRAB U.S. post marketing Pediatric Study, the first and only clinical trial to establish pediatric safety and effectiveness of any HRIG in the U.S. Additional evidence to support the use of KEDRAB in children comes from real world evidence. According to Centers for Disease Control and Prevention data, no children in the U.S. treated with post-exposure prophylaxis have been reported to have had rabies between 2018 and April 2021. Rabies is a life-threatening disease, but it is fully preventable if treated on time. It impacts approximately 40,000 people in the U.S. each year. According to the World Health Organization, up to 40 percent of people exposed to a suspected rabid animal are children under 15 years of age "Improving the lives of people with rare and serious diseases is our most important mission at Kedrion Biopharma," said Kedrion Biopharma Chief Executive Officer, Val Romberg. "As the U.S. market's first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication. Today's news will provide added peace of mind for physicians who choose KEDRAB in treating children who have possibly been exposed to rabies. We are especially proud of our partnership with Kamada, which has resulted in this significant step forward in global health."

07:07 EDT AC Immune provides update on Alzheimer's disease vaccine candidates - AC Immune provided key clinical and preclinical updates for its SupraAntigen-derived liposomal vaccine candidates, which are designed to convey active, long-lasting immunization against pathological forms of amyloid-beta. AC Immune is completing a Phase 2 study of its first clinical candidate, ACI-24, in people with mild Alzheimer's disease, and is also advancing an optimized ACI-24 formulation, which demonstrates enhanced and sustained immunogenicity in non-human primate studies, particularly against key pathological forms of Abeta such as oligomeric and pyroglutamate Abeta. Pyroglutamate Abeta is a highly neurotoxic form of Abeta that is N-terminally truncated and post-translationally modified to form pyroglutamate. Extracellular pyroGlu-Abeta is an important target for immunotherapy, as the peptide's altered biochemical properties make it more prone to aggregate compared to full-length Abeta, and it is a major component of Abeta plaques. Passive immunization with a monoclonal antibody specific for pyroglutamate Abeta demonstrated encouraging clinical results in a recently published Phase 2 clinical study. In non-human primates, vaccination with the optimized ACI-24 vaccine generated a strong, conformation-specific antibody response against oligomeric and pyroGlu-Abeta. A robust boosting effect was also observed, the magnitude of which was substantially greater against pyroGlu-Abeta compared to full-length Abeta. Epitope mapping studies using sera from immunized cynomolgus monkeys showed the strongest signals for sites binding to peptides covering N-terminal regions of Abeta located just beyond where cleavage occurs to form pyroGlu-Abeta. This further supports the strong response observed against this key pathological variant. In addition, AC Immune completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24 in patients with mild AD. Confirming earlier interim results, there have been no safety concerns nor evidence for CNS inflammation or ARIA related to ACI-24 in any subject. AC Immune will complete the Phase 2 study with the 24-month analysis on the basis of currently enrolled patients.

07:05 EDT Fury Gold Mines provides update on Eau Claire project - Fury Gold Mines is pleased to announce an updated geological framework that has enhanced the regional targeting at the Eau Claire project located in the Eeyou Istchee Territory in the James Bay region of Quebec. Targets have been refined through the re-interpretation of airborne magnetic and electro-magnetic surveys and associated 3D inversions. Target areas are defined by complex structural zones and associated favourable lithologies that highlight two distinct styles of mineralization: quartz-tourmaline vein systems, as observed at the Eau Claire deposit, and sedimentary hosted breccias that characterize the Percival prospect, located approximately 14 kilometres east of Eau Claire along the Cannard Deformation Zone. During the summer, Fury plans to advance the newly identified targets through multi-element geochemical surveys, geological mapping, and potentially ground based induced polarization geophysical surveys with the aim of drilling the most robust targets during Q4 2021. More importantly, the Company will conduct new geochemistry surveys over each of the target areas as the historical geochemistry data set had inconsistencies in sample collection procedures, material sampled and analytical techniques. These inconsistencies resulted in gold bearing prospects not being imaged in the historical dataset and an inability to interpret the geochemical values and their significance. Additionally, approximately 75% of the historical surface geochemical samples did not utilize multi-element assay techniques to define pathfinder elements for gold. Therefore, each of the target areas will employ biogeochemical surveys, which was used to successfully image the Percival prospect, accurately defining the gold and alteration footprints of each target area. An updated interpretation of the Percival prospect, discovered in 2018, indicated that high-grade mineralization is parallel to highly magnetic bodies representing a steeply plunging fold geometry. Based on recently completed 3D inversions of airborne magnetic data there is the potential to extend high-grade mineralization up to 500 metres down plunge from historical intercepts of 8.5m of 7.13 g/t gold, 9m of 6.26 g/t gold, and 2m of 8.47 g/t gold. In addition, the Company has identified a new parallel steeply plunging fold approximately 500m to the east of the known mineralization that has not been drill tested. The Company plans to conducted ground based geophysical induced polarization surveys to further refine the targeting at Percival to image the sulphide rich mineralization through the acquisition of chargeability data.

07:03 EDT Karyopharm's nexpovio receives conditional marketing authorization in U.K. - Karyopharm's Nexpovio, the company's first-in-class, oral Selective Inhibitor of Nuclear Export medicine has been granted conditional marketing authorization by the UK's Medicines & Healthcare Products Regulatory Agency, in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Conditional marketing authorization is supported by data from the positive Phase 2b STORM study, which evaluated selinexor in adult patients with heavily pretreated, triple class refractory multiple myeloma and was published in the New England Journal of Medicine in August 2019. Continued authorization for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial and is subject to additional monitoring. This marketing authorization follows a similar authorization granted by the European Commission and valid in all 27 European Union member countries announced on March 29.

07:03 EDT Hillenbrand Joe Raver to retire, Kimberly Ryan to succeed - Hillenbrand announced that Joe Raver, President and CEO, plans to retire at the end of 2021. The Board of Directors has appointed Kimberly Ryan to succeed Raver as CEO on January 1, 2022, at which time she will also join the Hillenbrand Board. She will become Executive Vice President of Hillenbrand effective immediately. Ryan's selection is the culmination of a robust, multi-year leadership development and succession planning process led by the Board with the help of an independent external management consultant. Ryan joined the Batesville Casket Company in 1989 and in her 33 years with Hillenbrand, has held many senior roles, including President of Batesville. Since 2015, she has been President of Coperion, Hillenbrand's largest business, where she built a strong management team and drove excellent results - achieving 30% revenue growth to approximately $1B in 2020 and over 500 basis points of improved EBITDA margin - while establishing Coperion as a clear global industry leader. The CEO transition begins June 2. Effective immediately, Ryan will have responsibility for the company's businesses, including Mold-Masters, Milacron Injection Molding & Extrusion, Coperion, and Batesville. The leaders of these businesses will report directly to Ryan, and she will lead the development and execution of their strategies and business plans to drive profitable growth. The other members of the company's Executive Management Team will continue to report to Raver during the transition. As EVP, Ryan moves out of her role as President of Coperion. Ulrich Bartel, President of Coperion's Polymer Division, has been named Coperion President and joins the Hillenbrand Executive Management Team, effective immediately.

07:00 EDT Pentair announces Social Responsibility Strategic Targets - Pentair announced its Social Responsibility Strategic Targets. The new targets were launched with the release of Pentair's 2020 Corporate Responsibility Report and include: reducing Scope 1 and 2 greenhouse gas emissions by 50% from a 2019 baseline by 2030, and aim to achieve carbon neutrality by 2050; targeting a 30% reduction in overall water withdrawal from a 2019 baseline by 2030; to further assess, design, and commercialize products for environmental sustainability to reduce customers' impact on climate change; to build a more sustainable supply chain, to refresh the Supplier Code of Conduct with increased focus on environmental sustainability and social responsibility in 2021, and launching an updated supplier assessment process in 2022; achieving an inclusive and diverse workforce and leadership team with a specific focus on increasing women in leadership positions globally and persons of color representation in U.S. leadership positions.

06:57 EDT Becton Dickinson authorized as CVE Numbering Authority - BD announced that it has become the first medical technology company authorized as a Common Vulnerability and Exposures Numbering Authority by the CVE Program. As a CVE Numbering Authority, BD is authorized to assign CVE identification numbers to newly discovered vulnerabilities in its software-enabled products. This includes using the Common Weakness Enumeration system to classify vulnerability types and applying the Common Vulnerability Scoring System to communicate vulnerability characteristics and severity. The purpose of the CVE Program is to bolster international cybersecurity defense by cataloguing publicly disclosed cybersecurity vulnerabilities. The CVE Program is sponsored by the U.S. Department of Homeland Security Cybersecurity and Infrastructure Security Agency and operated by MITRE Corporation.

06:55 EDT 3M, Bemis Associates enter agreement for 3M Scotchlite Reflective Material - 3M has entered an agreement with Bemis Associates Inc. to distribute and convert 3M Scotchlite Reflective Materials. The distribution agreement will leverage each brand's unique capabilities to serve sportswear and activewear brands globally with innovative and unique reflective solution offerings.

06:50 EDT Land's End CEO says 'extremely pleased' with Q1 results - Jerome Griffith, CEO, stated, "We are extremely pleased with our first quarter results, which exceeded our expectations and illustrate the sustained momentum in our business. Our Global eCommerce business is stronger than ever as we continued to execute our digitally led product and marketing strategies while the recovery in Outfitters is occurring at a faster pace than we expected. In addition to the better than expected revenue growth in the quarter, through gross margin expansion and effective cost controls, we delivered a $34.1 million improvement in Adjusted EBITDA, as we continued to focus on driving profitability. We believe we have a strong foundation in place and an expanding total addressable market, and I am extremely excited for our significant opportunities that lie ahead."

06:40 EDT eGain selected by Family Court of Delaware for virtual assistance channels - eGain has been selected by the Family Court of the State of Delaware for virtual assistance and live chat digital channels. The Family Court holds jurisdiction over domestic matters with multiple locations across the state. As part of COVID-19 social guidelines, to maintain citizen accessibility to information, the Family Court chose to expand their use of digital channels, with the goal of boosting both agent productivity and customer experience. eGain Virtual Assistant will provide users with general information and resources. The court's resource center agents will use eGain SuperChat to handle escalated issues that cannot be resolved by the Virtual Assistant.

06:37 EDT Advance Auto Parts raises FY21 adjusted operating income margin view to 9%-9.2% - Prior view was 8.9%-9.1%. Backs FY21: CapEx view $300M-$350M; tax rate 24%-26%; free cash flow minimum $575M; new store openings 100-150.

06:37 EDT Centogene begins study to identify patients with frontotemporal dementia - Centogene (CNTG) announced a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia. The observational EFRONT Study is being conducted with support from Alector (ALEC) under a commercial agreement, the financial details of which were undisclosed. Leveraging Centogene's proprietary Bio/Databank, the observational EFRONT Study aims to enroll and genetically test more than 3,000 FTD patients at participating centers in Europe.

06:35 EDT Novartis' Cosentyx gets FDA approval for children's plaque psoriasis - Novartis announced the U.S. Food and Drug Administration has approved Cosentyx for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. "This is the first approval for Cosentyx in a pediatric population in the U.S. The Cosentyx clinical profile is supported by five years of adult data showing long-lasting efficacy and a consistent safety profile across moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis," the company stated.

06:34 EDT KTH Royal Institute of Technology to establish Trimble Technology Lab - Sweden's KTH Royal Institute of Technology has received a gift from Trimble to establish a state-of-the-art Technology Lab for architecture, engineering and construction. The lab will expand the university's leadership in training and research in 3D building design, digital fabrication and the sustainable built environment. The Trimble Technology Lab will provide students enrolled in KTH's School of Architecture and the Built Environment hands-on experience with Trimble solutions. Applications of these solutions range from scanning buildings or sites, design and 3D printing of architectural building models and digital fabrication to implementing construction cost estimating and scheduling to improve productivity and reduce costs. Partnering with Trimble allows KTH to more fully integrate across its curricula the technological tools that are rapidly transforming how buildings and living environments are designed and constructed.

06:32 EDT Planet 13 'welcomes' Bill 341 allowing consumption lounge operations - Planet 13 Holdings welcomes recently passed bill 341 allowing existing licensed dispensaries to operate a consumption lounge co-located with the dispensary. Planet 13 has reserved a dedicated space within the Las Vegas SuperStore for a consumption lounge which it will look to get built as soon as possible. "We are thrilled that after the long wait, Nevada will finally be home to consumption lounges. We've long believed that tourists needed a safe, legal, and enjoyable place to consume cannabis and have been planning for a consumption lounge at the SuperStore since the bill was originally proposed two years ago," said Bob Groesbeck Co-CEO of Planet 13. "Our SuperStore is one of the only dispensaries with the space on site and the proximity to the Las Vegas Strip to create a truly Vegas style club. As with the rest of our dispensary we look forward to setting the bar and showing the industry what is possible when your goal is to Out Vegas, Vegas."

06:22 EDT China Yuchai forms strategic partnership with Sunlong to develop EVs - China Yuchai International announced it has entered into a strategic partnership agreement with an electric vehicle bus producer in China, Guangxi Shenlong Automobile Manufacturing. According to the strategic partnership agreement, China Yuchai and Sunlong will join technologies to develop new energy vehicles based upon China Yuchai's four new energy powertrain systems including the ISG power generation powertrain, e-CVT power-split hybrid powertrain, integrated electric drive axel powertrain, and a fuel cell system. In addition to product development, China Yuchai and Sunlong will leverage each other's supply chains and distribution networks, especially in international markets, with a focus on entering into the southeast Asian markets. Headquartered in Nanning, Guangxi Province, Sunlong specializes in new energy buses, and logistical vehicle development and production in southern China. In the past, China Yuchai has supplied its electric direct drive system, hybrid system and Nat VI-compliant CNG natural gas engine to Sunlong for its vehicles sold in southern and western China. In April 2021, the first batch of Sunlong buses featuring China Yuchai's new energy powertrain systems was delivered to the Nanning local public transit operator.

06:18 EDT Socket Mobile offers compatibility with EU Digital COVID Certificates - Socket Mobile announce d that its entire family of barcode scanners offer out-of-the-box support for applications designed to facilitate EU Digital COVID Certificates. On May 20th, the European Commission announced a "provisional political agreement between the European Parliament and the Council on the Regulation governing the EU Digital COVID Certificate." The Certificate will facilitate travel within EU borders by providing information such as vaccination, test and recovery status via a digitally signed QR code. To encourage a timely roll-out, the Commission will provide member states with open-source reference software. EU member states will then develop their own applications to issue certificates and scan and check QR codes.

06:12 EDT National Energy Services awarded oil company contracts for $150M - National Energy Services reported multiple contract awards with major international oil companies for Integrated Rigless Services and Drilling and Completion Fluids in the Middle East and North Africa region which will be executed over the next three years for up to $150M.

06:10 EDT Elbit Systems awarded $80M contract for AI-powered optical systems - Elbit Systems was awarded an approximately $80M contract by a country in Asia-Pacific to supply Spectro XR multi-spectral electro-optic systems for maritime forces. The contract will be performed over a period of four years. Elbit Systems will supply Spectro XR EO systems that will be integrated onboard a variety of maritime platforms. Using Artificial Intelligence, Spectro XR applies multi-target video tracking, Moving Target Indication and Video Motion Detection to continuously scan for targets, extract operational insights and reduce human error.

06:08 EDT AstraZeneca's Anifrolumab demonstrated benefit across measures of skin disease - The company states: "A new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus, or SLE. The analysis examined disease manifestations in the two most commonly impacted organ domains in SLE. Anifrolumab is a potential first-in-class type I interferon inhibitor. For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index . For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. The most frequently reported adverse events for anifrolumab in the TULIP-1 and TULIP-2 trials were upper respiratory tract infection, bronchitis, infusion-related reactions and herpes zoster. AstraZeneca's application for anifrolumab in SLE is under review by regulatory authorities in the US, EU and Japan, with decisions anticipated in the second half of 2021. Anifrolumab is not currently approved in any country. Reference Link

06:07 EDT Macerich issues 2020 Corporate Responsibility Report - Macerich issued the Company's Corporate Responsibility Report with data for the period ending December 31, 2020. Macerich's comprehensive new report for 2020 details the Company's people-first response to COVID-19, active local stewardship and philanthropy, and commitment to fostering employee wellness and satisfaction. The report also conveys Macerich's continuing environmental leadership in the retail real estate industry, including plans to achieve carbon neutrality by 2030 - decades ahead of the Paris climate agreement. As well, Macerich's 2020 report demonstrates the Company's transparent approach to ethical practices and governance.

06:06 EDT High Tide bgins trading on Nasdaq - High Tide announced that the Company's common shares will commence trading today on the Nasdaq Capital Market under the ticker symbol "HITI". The Company's Nasdaq listing is expected to increase access to investment in High Tide from retail and institutional investors around the world. Furthermore, with access to a much larger capital market, the Company expects to improve liquidity for its Common Shares and, in turn, optimize its cost of capital. High Tide continues to retain its listing on the TSX Venture Exchange under the symbol "HITI". The ticker used for the Common Shares traded on the OTC Markets quotation system under the current symbol "HITID" has been seamlessly transferred to the new ticker symbol "HITI".

06:04 EDT IBM to establish IBM Center for Government Cybersecurity - IBM (IBM) announced that it is creating the IBM Center for Government Cybersecurity, a collaborative environment focused on helping federal agencies address current and future cybersecurity threats. The company said, "The center will facilitate events and learnings, drawing on IBM's cybersecurity expertise from delivering software and managed services to over 17,500 security customers globally. Working with a group of internal IBM experts and external advisors, including former government officials with decades of cybersecurity experience, the center will leverage IBM technology and host workshops focused on priorities such as zero trust frameworks and cloud security, complemented by access to IBM Research labs to collaborate around the future of encryption. As recent threats like SolarWinds (SWI) and the Colonial Pipeline ransomware attack against critical infrastructure have shown, the threat landscape has crossed over from the digital world to the physical. In fact, the 2021 IBM Security X-Force Threat Intelligence Index found that ransomware accounted for 33% of the attacks on government organizations in 2020. With the US Federal government furthering its investment in hybrid cloud, new approaches for cybersecurity should focus on protecting both systems as well as data - no matter where it is - either on premise, in the cloud, or at the edge." The IBM Center for Government Cybersecurity will be housed at IBM's offices in downtown Washington DC. The new facility will feature secured laboratory space where government customers can collaborate on unique solutions for advanced security threats leveraging insights from demos of IBM technologies and services. Initially, IBM will conduct virtual sessions to accommodate any challenges to meeting in person, with the capability to execute engagements at on-site customer locations. A central goal of the IBM Center for Government Cybersecurity is to provide access to information on cybersecurity technologies IBM is using with the public and private sectors, and security innovations being developed in IBM Research laboratories via workshops. Some of initial examples of the sessions IBM will conduct include: Adapting to a Zero Trust World; Hybrid Cloud Security Challenges for Data Portability; The Future of Cryptography.

05:57 EDT Esports Technologies names Mark Thorne as Chief Marketing Officer - Esports Technologies announced the appointment of accomplished gaming industry veteran Mark Thorne as its new Chief Marketing Officer. Thorne brings nearly 20 years of industry experience to the executive team, having served in leadership roles with Betfair, GVC, Betfirst, Bonnier Gaming, and Twin.com. He will report directly to Aaron Speach, Esports Technologies CEO.

05:53 EDT Amazon.com postpones Prime Day plans in Canada, India - The company said, "Due to the increasing impact of COVID-19 in Canada and India, we have decided to postpone Prime Day plans in those countries while we focus on the safety of our employees and on supporting our customers and selling partners. Stay tuned for details about Prime Day in these countries. Amazon.ca is donating $1.5 million for COVID-19 relief to the Canadian Red Cross, United Way of Canada, and True North Aid. All of these organizations provide much-needed support services in the communities we operate in, and we will continue to support the work they are doing across Canada. Amazon.in is providing COVID-19 health insurance, completely free of cost, for its sellers. The insurance will help cover the expenses related to COVID-19 hospitalization and treatment as well as ambulance assistance and ICU charges of up to INR 50,000, and it will be valid for one year after activation. Amazon is also partnering with several nonprofits across the country to donate hygiene aid kits, personal protective equipment kits, and groceries in support of healthcare workers and communities most affected by COVID-19."

05:49 EDT Moderna enters production agreement with Lonza in the Netherlands - Moderna announced that it has entered into an additional agreement with Lonza to support drug substance manufacturing for its global supply chain. The agreement will establish a new production line at Lonza's Geleen site in the Netherlands, contributing to the supply of an additional 300M doses of Moderna's updated booster variant vaccine candidate, if authorized, per year, at a 50 microgram dose. In addition to previously announced investments in drug substance manufacturing with ROVI in Granada, Spain, the company now expects to be able to supply the equivalent of 600M 50 microgram doses per year from production within the European Union. Both new drug substance lines in the European Union are expected to be operational before the end of 2021.

05:44 EDT Tesla CEO says supply chain 'biggest challenge,' but not long-term issue - Tesla CEO Elon Musk said via Twitter, "Our biggest challenge is supply chain, especially microcontroller chips. Never seen anything like it. Fear of running out is causing every company to overorder - like the toilet paper shortage, but at epic scale. That said, it's obv not a long-term issue." Musk was responding to a tweet that read: "Quick thought - Fact: $TSLA is shipping cars from China to Europe and increasing prices in the U.S. underlying reality: demand in the US is insane, Tesla has to increase prices and keep all local production onshore to manage it. 2Q21 print will be interesting!"